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Inflammatory bowel disease (IBD) is a collection of chronic, immune mediated disorders 
of the gastrointestinal track, characterized by relapsing and remitting disease activity. Despite 
our growing understanding of risk factors associated with developing disease, we still lack 
understanding of the impact of disease complications and how to best avoid complications with 
preventive care. Two known complications of IBD include the increased predisposition to 
Clostridium difficile infection and the increased risk of non-melanoma and melanoma skin 
cancers. This thesis aims to (1) define the long-term impact of Clostridium difficile infection on 
IBD patients after accounting for patients’ inherent risk of infection, (2) evaluate the rate at 
which IBD patients access dermatologic preventive care for skin cancer screening, and (3) model 
the cost-effectiveness of melanoma screening strategies in the IBD patient population.  
We found that Clostridium difficile infection was significantly associated with more 
steroid and antibiotic exposure, elevated inflammatory markers, increased disease activity, worse 
quality of life, and increased healthcare utilization in the year of infection. During the year after 
infection, patients in the Clostridium difficile group continued to have increased exposure to 
Clostridium difficile targeted antibiotics and other systemic antibiotics, while having more clinic 
visits, telephone encounters, and a five-fold increase in healthcare charges. 
We determined that 21% of IBD patients utilized dermatology from 2010-2016, and 2.6% 
of patients had at least one total body exam for skin cancer screening. Between 8% and 11% of 
patients recommended by gastroenterology preventive care guidelines visited dermatology each 
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year, suggesting only a small proportion of IBD patients recommended for screening obtain 
dermatologic care. 
Finally, we used a Markov model to estimate intervention costs and effectiveness of 
melanoma screening in the IBD population. We found screening for melanoma in IBD patients 
was more effective, but expensive. Among model variations, screening every other year was the 
most cost-effective strategy.  
In conclusion, the dissertation reveals the long-term impact of infection among IBD 
patients, the underutilization of dermatologic preventive care, and provides a cost effectiveness 
model to inform the development of skin cancer screening programs in IBD. 
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1.0  INTRODUCTION  
1.1 INFLAMMATORY BOWEL DISEASE (IBD) 
1.1.1 Epidemiology of IBD 
The inflammatory bowel diseases (IBDs), consisting primarily of Crohn’s disease (CD) 
and ulcerative colitis (UC), are complex immune-mediated disorders of the gastrointestinal tract 
affecting over 3 million people in Europe and North America with an increasing incidence of 
39.4 cases per 100,000 person years in North America.1–3 IBD is associated with increased 
morbidity and mortality, resulting in $6.3 billion in direct healthcare costs.4,5 Although the 
etiology of IBD is unknown, complex interactions between diet, environment and the immune 
system of a genetically susceptible host are thought to contribute to the development and natural 
history of IBD.6  
1.1.2 Complications of IBD 
There are a number of known complications of IBD, including gastrointestinal infection, 
malnutrition, extraintestinal manifestations of disease, increased risk of intestinal and 
extraintestinal malignancy, and side effects attributed to medication exposures.7–10 IBD is 
frequently associated with a multitude of psychiatric comorbidities of disease including poor 
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quality of life, depression, and anxiety.11 Abdominal pain contributes further to psychiatric 
complexities of IBD, as many patients rely on pain management to cope with their symptoms.12–
14 Throughout our work we have discovered that complications of disease, especially psychiatric 
complications and pain, are associated with increased financial healthcare charges, which 
contribute to the overall cost burden of IBD.15–17 Understanding the natural history of 
complications and implementing strategies to prevent IBD related complications has the 
potential to reduce overall cost of care while positively impacting patient care and wellbeing.  
1.1.2.1 Clostridium difficile infection 
The enteric pathogen Clostridium difficile has become an increasingly challenging and 
costly complication in IBD. Unfortunately, the incidence of Clostridium difficile infection (CDI) 
in IBD is increasing.18 CDI in IBD is associated with increased healthcare charges and longer 
hospital stays.19,20 While traditional risk factors of antibiotic exposure and healthcare contact 
contribute to the development of CDI, recent studies have suggested that IBD patients 
themselves are at an increased risk for primary CDI, and have a significantly greater chance of 
developing recurrent CDI compared to the general population.21,22 It is hypothesized that the 
increased risk of initial infection and recurrent CDI in IBD is related to disease inflammation, 
dysregulated immune system, and gut microbiome dysbiosis.23 
Despite our growing appreciation of the severity of CDI in IBD, there is still much that 
we do not know. It is unknown how the natural history of disease changes after infection, and if 
there are long-term effects on healthcare utilization. We also assume from the literature that CDI 
results in increased healthcare utilization, but the quantification of these changes in the year after 
infection is not clearly defined, as appropriate controls for these studies have been limited.  
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1.1.2.2 Extraintestinal manifestations  
In addition to infectious complications of IBD, many patients experience extraintestinal 
manifestations of IBD. It is estimated that 40% of patients will experience extraintestinal 
manifestations, with complications of the skin being one of the most common.24 Between 22-
75% of CD patients, and 5-11% of UC patients are thought to have mucocutaneous findings that 
are associated with IBD.25 There is a range of cutaneous findings associated with IBD. Certain 
cutaneous findings are related to disease severity and IBD pathophysiology including pyoderma 
gangrenosum and oral aphthous ulcers, while others are more generally associated with IBD 
including erythema nodosum and psoriasis.25 Finally, there are cutaneous complications of IBD 
that are due to adverse reactions of medications including shingles and generalized rash.8 Despite 
the high percentage of patients that are likely to experience dermatologic problems, it is 
uncertain how many IBD patients are actively seeking dermatologic care, and for what reasons.  
1.1.2.3 Skin Cancer  
A subset of skin complications in IBD includes the increased risk of melanoma and non-
melanoma skin cancers (NMSC).26–28 IBD is associated with a 37% increase in the risk of 
melanoma, a figured which is thought to be independent of medication exposure.26 There are also 
studies that suggest medication exposures may increase the risk of melanoma even further 
among IBD patients exposed to biologics.28–30 An estimate of the incidence rate ratio for NMSC 
in IBD compared to controls is 1.64 (95% CI: 1.51-1.78).27 Medication exposures, especially 
thiopurines, are thought to contribute to the burden of NMSC in IBD.31 Interestingly, many 
gastroenterologists surveyed were unaware of the risk of NMSC and its association with 
medication exposures.32 This suggests that patients may need to self-advocate for skin cancer 
screening and dermatologic care. However, is unknown how many IBD patients undergo skin 
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cancer screening though a total body skin exam. It is also unknown if the proportion of patients 
who obtain skin cancer screening aligns with medication exposures and age as recommended by 
the current IBD specific preventive care guidelines.  
Finally, a handful of studies over the last two decades have evaluated the cost-
effectiveness of melanoma screening programs.33–36 Annual population-wide screening is likely 
cost prohibitive due to low prevalence of melanoma, and may result in unnecessary morbidity 
from screening in low risk persons. Previous cost effectiveness studies agree that screening high-
risk patients, in contrast to the entire population, for melanoma may be the most cost-effective 
strategy. However, the cost effectiveness of melanoma screening has not been evaluated in the 
IBD population. Additionally, the published cost effectiveness studies model screening strategies 
that may be difficult to translate to IBD patients, including primary care based screening and 
within a clinical trial.35,36 Therefore, it is still uncertain of how the cost-effectiveness of 
screening by a dermatologist translates to IBD patients with intermediate risk.  
1.2 STATEMENT OF PROBLEM AND MAJOR QUESTIONS 
There are many complications of IBD that are not sufficiently addressed in the literature. 
We will begin by outlining the methodology of generating large, real-world observational data 
from the electronic medical record to facilitate in-depth patient phenotyping in IBD. The 
methodology and data generated from the IBD research registry are used to support the clinical 
questions addressed in the first two dissertation subprojects.  
As incidence and awareness of CDI in IBD are increasing, we are beginning to 
understand some of the risk factors associated with infection. However, we are still uncertain 
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how patients’ natural history of disease is modified after infection. We will address this gap in 
the literature in our first dissertation sub-project by generated a propensity matched control 
cohort to which we can compare IBD patients with CDI before, during, and after infection. 
There has also been a growth in our understanding of the extraintestinal manifestations of 
disease, and the increased risk of dermatologic malignancies in IBD. However, it is unclear how 
physician preventive care guidelines translate into patterns of dermatologic care. The second 
sub-project in this dissertation aims to understand the rates of and reasons fore dermatologic care 
among IBD patients with an emphasis on skin cancer screening.  
Finally, while guidelines recommending skin cancer screening among IBD patients exist 
in the literature, these have not been broadly implemented in clinical care. Therefore, we will use 
Markov models to evaluate the cost-effectiveness of melanoma screening in IBD patients in the 
last sub-project of the dissertation. 
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2.0  IBD RESEARCH REGISTRY METHODOLOGY 
Adapted with permission from publication in Digestive Diseases & Sciences: 
 
Development of an Inflammatory Bowel Disease Research Registry Derived from Observational 
Electronic Health Record Data for Comprehensive Clinical Phenotyping 
 
Alyce J. M. Anderson1, Benjamin Click2, Claudia Ramos-Rivers2, Dmitriy Babichenko3, Ioannis 
E. Koutroubakis2, Douglas J. Hartman4, Jana G. Hashash2, Marc Schwartz2, Jason Swoger2, 
Arthur M. Barrie III2, Michael A. Dunn2, Miguel Regueiro2, David G. Binion2 
 
1School of Medicine, University of Pittsburgh, Pittsburgh, PA. 
2Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University 
of Pittsburgh, Pittsburgh, PA. 
3School of Information Sciences, University of Pittsburgh, Pittsburgh, PA. 
4Department of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA. 
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2.1 INTRODUCTION 
Inflammatory bowel disease (IBD) consists of two main entities: Crohn’s disease (CD) 
and ulcerative colitis (UC). IBD is estimated to affect up to two million Americans, with an 
increasing annual incidence of 39.4 cases per 100,000 person years in North America.2 CD and 
UC result in morbidity, disability, and heightened mortality, generating approximately $6.3 
billion in direct healthcare costs and an additional $3.6 billion in indirect costs due to loss of 
productivity.4,5,37 The clinical course of IBD is variable and often unpredictable. IBD severity 
ranges from mild symptoms to severely debilitating disease. Therefore, IBD encompasses a large 
spectrum of severity, disease duration, disease course, and complexity of disease-related extra-
intestinal manifestations. This heterogeneity of disease over time and across individuals 
significantly limits our ability to translate results from randomized controlled clinical trials into 
clinical practice.38 For example, the effectiveness of therapeutic drugs varies over time within 
individuals, and across individuals with different degrees of IBD severity.39–41  
Given our incomplete understanding of disease heterogeneity, and the inherent 
limitations of clinical efficacy studies in IBD, we sought to define clinical subtypes of disease by 
examining disease course patterns and the effectiveness of medical therapy in a tertiary care 
clinic. To this end, we developed a research registry of IBD patients at UPMC. The aims of the 
IBD research registry are to: (1) organize clinical information and define the natural history of 
IBD; (2) develop a research platform for association studies and the delineation of clinical 
phenotypes; and (3) examine effectiveness and quality of care measures in the setting of IBD. 
We propose that a database using prospective observational health record data will support and 
facilitate natural history, disease phenotyping, and effectiveness research in chronic illness. This 
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manuscript details the design, development, challenges faced, and implementation of the IBD 
research registry at a large tertiary care center in the US. 
2.2 METHODS 
2.2.1 Registry Setting 
The IBD research registry is an IRB-approved patient registry maintained at UPMC in 
Pittsburgh, PA. The registry was created in 2001 by a gastroenterologist who is also the Principal 
Investigator (MR). The Principal Investigator originally began enrolling IBD patients in the 
National Institutes of Digestive, Diabetes and Kidney Disease genetics consortium and used the 
registry in parallel to prospectively consent all IBD patients visiting the UPMC Digestive 
Disorder Center. The rationale for the initial development of the registry was to gather clinical 
data for IBD patients who were participating in the genetic discovery arm of the consortium. The 
registry was initially managed as a research tool, outside of the daily clinical practice and 
clinician access. In 2008, an initiative was formed to incorporate observational healthcare data 
into the registry. To achieve this goal, the registry was moved into an electronic, Health 
Insurance Portability and Accountability Act (HIPAA) secure environment that could be readily 
accessed by gastroenterologists, support staff, and IRB-approved research collaborators. 
Concurrently, UPMC introduced an outpatient electronic health record system (EpicCare, Epic 
Systems, Verona, WI, USA) for all affiliated sites in the UPMC system, which includes over 20 
hospitals and 500 clinics across Western Pennsylvania. This system-wide electronic medical 
record allowed all clinical data across numerous healthcare facilities to be captured.   
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2.2.2 Registry Enrollment 
The target population for the registry is adult IBD patients, 18 years of age and older. 
This population is derived from patients presenting to the Digestive Disorders Center at UPMC, 
a tertiary care clinic with physicians with IBD expertise. Recruitment for the IBD research 
registry is ongoing and in perpetuity.  As a part of the initial clinic visit, all patients are provided 
a consent form with a description of the IBD registry. All IBD physicians and their staff are co-
investigators on the registry.  At the time of the clinic visit, the registry is explained to the patient 
by a co-investigator and the patient has the opportunity to ask questions.  The patient may choose 
to sign the registry consent during the clinic visit, may decline enrollment in the registry or may 
elect to take the consent with them to review further and ask additional questions. The consent 
form describes the participation risks including the most significant potential risk of a breach of 
confidentiality. Within the consent form, we request access to medical records for research 
purposes and the ability to approach enrolled patients for future research studies, both of which 
are critical for ongoing research and recruitment. The consent form does not have a menu of 
options to avoid unnecessary complexity. Any new research initiatives that would like to link 
data to the UPMC IBD Registry, or request biological samples, require a separate consent. 
Patients may withdraw from the registry at any point, and these procedures are outlined in the 
consent. Patients are also offered the opportunity to participate in the registry during follow-up 
care. Participation in the registry is optional and all patients receive the same clinical care 
whether they are included in the registry or not. 
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2.2.3 Registry Design and Measures 
Variables imported into the IBD research registry are generated as a part of routine 
outpatient clinical care. Data extraction from the electronic medical record (EMR) for the 
purpose of the IBD registry has been occurring since 2009. Clinical data for patients enrolled in 
the registry are systematically exported from the EMR through the Center for Assistance in 
Research using eRecord at the University of Pittsburgh, an information technology support 
group. Data is retrieved from the EMR biannually, categorized according to clinical domain 
(medications, radiology, laboratories, etc.), and delivered electronically to the registry research 
team. Automated and manual data transformations are used to separate all values into domain-
specific data-sets. Clinical events are categorized as binary (categorical) outcomes (0,1) for 
initial statistical analyses. Laboratory values are imported as raw numbers and are further defined 
as normal or abnormal (0,1). Annual dichotomous patterns for clinical events, medication 
prescriptions, and abnormal laboratory values are created. The exact dates of these data points 
are also preserved for time-to-event analyses.  All data are stored behind the HIPPA-compliant, 
password-protected UPMC firewall, in a secure environment; only accessible by co-investigators 
listed on the IRB approval who have completed appropriate human subjects research training. 
Master data lists are password-protected and archived for data integrity.  
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Figure 1. Flow diagram of inflammatory bowel disease research registry 
Abbreviations: IBD – Inflammatory bowel disease, H&P – History and physical 
 
In order to provide access to the data for research collaborators, and to enable advanced 
data analysis, the data is completely de-identified and imported into a relational database or 
statistical package.  The de-identification process creates unique identifiers for each record and 
generates a patient lookup list used to link the original data structure. This lookup list is stored 
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behind the UPMC firewall, and patient identifiers are separated from the data. The relational 
database is deployed on a secure HIPAA-compliant server accessible via a virtual private 
network by co-investigators listed on the IRB approval. The de-identification process also allows 
for collaboration with outside institutions if multi-site collaborations arise.  
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Table 1. Measurements collected in the inflammatory bowel disease research registry 
Patient demographics  
Disease related information 
Age at diagnosis 
Disease duration 
Disease localization according to Montreal classification 
Disease phenotype according to Montreal classification 
Patient questionnaires 
SIBDQ 
HBI 
UCAI 
Endoscopic data 
Pathology (surgical and procedural) 
Radiological data  
Comorbidities – ICD9 codes 
Laboratory 
Standardized IBD lab panel  
Fecal microbial testing including Clostridium difficile 
Medications 
IBD related prescriptions 
Other prescriptions 
Healthcare Utilization 
IBD clinic visits 
Emergency department visits 
Hospital admissions 
Telephone encounters 
Radiology 
Surgical procedures 
Total charges for healthcare services 
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Variables collected include demographic information (Table 1) and initial IBD 
classification of CD or UC. Related comorbidities are recorded through the use of administrative 
International Classification of Diseases, Ninth Revision and Tenth Revision (ICD-9, ICD-10) 
codes and EMR problem lists. Laboratories, vitals and objective data collected and entered into 
the EMR during the patient visit are organized by subject and visit date. Healthcare utilization 
measures include telephone encounters, emergency department visits, IBD clinic visits, hospital 
admissions, endoscopic and radiologic procedures, and surgeries. Financial healthcare charges 
are also organized by year. Medication data includes prescriptions for biologics, 
immunomodulators, steroids, 5-aminosalicylates and iron supplementation for each calendar 
year. Data on psychiatric and opiate pain medications are also collected as markers comorbid. 
Additional medications that are not part of routine IBD care can be retrieved using search 
algorithms.  
As a part of the standardized visit in the UPMC Digestive Disorders Center, each patient 
is asked to complete health related questionnaires, such as the published version of the Short 
Inflammatory Bowel Disease Questionnaire (SIBDQ), the Harvey-Bradshaw Index for CD 
(HBI), and an ulcerative colitis activity index (UCAI) for UC.42–44 The questionnaires are 
administered at every visit to inform clinical care, regardless of a patient’s registry inclusion 
status. Patients complete hard copies of the questionnaires in their clinic room. Individual 
component sub-scores and total scores for each visit are recorded in the EMR by clinic support 
staff and are available for export into the registry. These standardized clinical measures allow 
prospective measurements of patient-reported disease clinical activity and health-related quality 
of life.  
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The outpatient EMR has many standard data entry fields, which can be exported in 
collaboration with the Center for Assistance in Research using eRecord at the University of 
Pittsburgh. When research projects would benefit from the addition of a variable that is collected 
in clinical care, we can make additional data extraction requests for retrieval of this data. One 
example would be family history of IBD and other co-existent diseases.  This data is routinely 
collected at patient visits and was not originally a part of the initial pre-specified registry dataset. 
Requesting new information allows the research team the ability to create and manipulate new 
variables and populations of interest as new research questions arise. 
In addition to data collected in standard data entry fields, the outpatient record contains 
health information that is not standardized in the patient chart. This valuable information appears 
in patient discharge summaries, surgical notes, endoscopic reports, pathology reports, clinic 
notes, and other free text entry fields. Text data from free entry fields is exported into the IBD 
research registry in de-identified ASCII text files, which allows for the use of natural language 
processing toolkit and the R Project for Statistical Computing for analysis and retrieval of textual 
information from free text files.45,46 We recently began work on implementing a combination of 
Apache openNLP natural language toolkit and Apache cTakes natural language processing 
(NLP) system for extraction of information from clinical free-text to improve the processing of 
natural language text.47,48 There are several major challenges to extracting meaningful 
information from free text data, such as pathology or endoscopy reports. These challenges 
include lack of structure in the narrative, multiple spellings and synonyms for terms of interest, 
as well as issues with context negation. For example, when extracting presence or absence of 
Clostridium difficile from pathology reports, 16 different spellings for “Clostridium difficile” 
were found. In order to address these issues, we began to use NOBLE tools developed at the 
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University of Pittsburgh Department of Biomedical Informatics to create dictionaries and 
ontologies for terms of interest.49 Furthermore, NOBLE tools have built-in NLP support for 
identifying context negation, helping resolve issues with false positive term identification. While 
this approach is still in its development phases, we have been validating its accuracy with manual 
search and classification of terms of interest. 
2.2.4 Quality Assurance 
The IBD clinic has a standardized intake visit and also standard lab panels which help 
facilitate more uniform data capture. Many of these uniform datasets and data capture strategies 
are utilized at the goodwill of clinicians. Our clinicians are not incentivized to use certain notes 
or pre-populated laboratory order sets. Data quality and integrity is monitored by manual review 
after data export. Data validation occurs at the extreme values of each measure. For example, a 
patient weight is verified if the value does not fall within a pre-specified data validation range. 
Random manual EMR verification (“spot checking”) is also performed on each data set to ensure 
accuracy. Data linkage and matching is performed using unique patient identifiers. Missing data 
is imputed using the medical record, and manual data extraction from the EMR is performed on a 
case-by-case basis.  
2.2.5 Registry Team 
The registry is coordinated by an analytical research scientist who processes data 
extraction requests and organizes master files. We have found that having a dedicated staff 
member has revitalized the UPMC IBD Registry. The staff analytical research scientist allocates 
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duplicate data appropriately to active researchers, preserving data integrity of the master files. 
Trained clinical personnel consent individuals to join the registry. Hard copies of disease activity 
indices and quality of life metrics are completed by patients in their clinic rooms, and entered 
into the official medical record by clinical support staff. All other research related operations, 
including the data entry of research questionnaires, are assigned to the primary investigator on 
each IRB approved sub-study. We also receive information technology assistance from the 
Center for Assistance in Research using eRecord at the University of Pittsburgh, and data science 
collaborators from University of Pittsburgh, School of Information Sciences.  
2.2.6 Ethical Considerations 
The research registry is an IRB approved protocol (Protocol # 0309054), open for 
continuous enrollment and undergoes renewal as dictated by IRB regulations. All subsequent 
data linkage protocols and research questions involving the database require separate IRB 
approval to ensure the protection of human subjects. Subjects are able to withdraw from the IRB 
research registry at any time with a written request to the principal investigator.  
2.3 RESULTS 
The initial registry cohort, in collaboration with other NIDDK genetics consortium 
institutions, has been an instrumental part of published genome wide association studies and 
other genetic discoveries in IBD.6,50 With ongoing enrollment, the registry continued to grow 
after the revitalization initiative in 2008, and currently includes over 2,565 patients participating 
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in the IBD research registry (Table 2). Using annual visit trends, we estimate that approximately 
70% of the IBD patients in our clinic are actively participating in the registry.  Each newly 
consented registry participant provides us with new data going forward, but also all retrospective 
data contained in their outpatient EMR from 2009 to the time of the data pull. This allows for 
backfilling of the data for each new registry member while avoiding manual chart review. IBD 
registry participants represent over 700 unique zip codes and represent a wide geographic area 
(Table 2). The median age is 43.8 years, and the vast majority of participants are Caucasian, 
while just under half the participants report full time employment (Table 2). 
 
Table 2. Inflammatory bowel disease research registry demographics 
IBD Registry Participants (n) 2565 
Age*, years (median, IQR)  43.8 (32.9-57.6) 
Race, n (%)  
Black 60 (2.3) 
White 2390 (93.2) 
Other 8 (0.3) 
Not specified 107 (4.2) 
Living Status (n, % alive) 2500 (97.5) 
Number of Zip Codes 748 
Employment Status, n (%)  
Full time 1184 (46.2) 
Part time 59 (2.3) 
Self employed 60 (2.3) 
Student 190 (7.4) 
Retired 206 (8.0) 
Not employed 460 (17.9) 
Not specified 403 (15.7) 
*Age calculated as of October 1, 2015; IQR: interquartile range 
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Disease related information is a critical component of the registry with nearly 90% of 
IBD registry participants having defined disease phenotype based on Montreal Classification 
(Table 3).51 The average disease duration is 17.4 years and 22% of patients have had a history of 
IBD-related surgery prior to 2009 (Table 3). Nearly half of the participants have CD (Table 3). 
 
Table 3. Inflammatory bowel disease research registry disease information 
 Total, (%) 
Disease classification, n (%)  
Crohn’s disease 1313 (51.2) 
Ulcerative colitis 910 (35.5) 
Indeterminate colitis 7 (0.3) 
IBD - Unclassified 190 (7.41) 
Disease duration, median (IQR)  15.0, (10-22) 
Patients with Montreal Classification, n (%) 2238 (87.3) 
Patients with history of IBD surgery, n (%) 563 (22.0) 
IBD questionnaires (n; median, IQR)  
SIBDQ 
 
9905 
52 (40-61) 
HBI 10446 
4.84 (0-55) 
UCAI 10446 
2.0 (0-6.0) 
Abbreviations: IQR – interquartile range, IBD – Inflammatory bowel disease, SIBDQ – Short 
inflammatory bowel disease questionnaire42, HBI – Harvey Bradshaw Index43, UCAI – 
Ulcerative colitis activity index44. 
 
The effort to achieve our primary aim to organize prospectively collected, longitudinal 
clinical information has resulted in over 500 gigabytes of temporally organized data. We have 
organized over 1.3 million laboratory values and 124,658 prescriptions since 2009 (Table 4). 
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Routinely collected utilization measures, including office visits, telephone calls, surgeries, 
hospitalizations, emergency room visits and radiologic or endoscopic procedures have been 
organized by year (Table 4). We have organized over $310 million of total financial healthcare 
charges incurred by patients in the IBD registry and are exploring financial charge data as a new 
phenotype of disease severity (Table 4). 
Table 4. Inflammatory bowel disease research registry total number of measurements 
 Total Number Organized 
Laboratory values 1,308,993 
Clinic visits 36,747 
Telephone encounters 645,888 
Emergency room visits 7,378 
Hospital admissions 3,508 
Endoscopies 8,472 
Surgeries 1,304 
Radiology (n)  
CT 7,716 
MRI 2,585 
X-ray 10,569 
Comorbidities* 2,152 
Prescriptions  
Biologics† 5,976 
Immunomodulators 6,897 
Systemic steroids 6,867 
5-ASA 4,652 
Other 100,236 
Total charges organized ($) $310.3 Million 
Abbreviations: 5-ASA - 5-aminosalicyclic acid medications. 
* Based on the International Classification of Diseases, Ninth Revision (ICD-9) codes contained 
in patient specific problem lists. 
† Biologics included anti-tumor necrosis factor agents (Infliximab, Adalimumab, Certolizumab 
pegol)   
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Our second aim was to develop a research platform for the definition of clinical 
phenotypes. The data has resulted in multiple clinical phenotypes that have been published and 
are associated with increased levels of healthcare utilization or predictive of poor disease 
outcomes (Table 5). These phenotypes include patients with high volume telephone calls, 
persistent or recurrent anemia, CRP elevations and peripheral eosinophilia.52–56 We developed a 
set of tools written in Python programming language to search unstructured text data and identify 
patients with features of interests.  These features included presence of granulomas on pathology 
reports, as well as presence or absence of Clostridium difficile in endoscopy reports, both of 
which have resulted in meaningful subgroups for analysis.57,58 Projects are underway to link the 
clinical phenotypes to genotype signatures and utilize genetic data to understand the relationship 
of drug metabolism polymorphisms and patient data in our population. 
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Table 5. Example clinical phenotypes explored using the inflammatory bowel disease research 
registry 
Phenotypes Risk of adverse health outcome 
Silent Crohn’s disease: 
CRP elevation without clinical symptoms53 
Increased risk and rate of hospitalization 
Persistent/recurrent anemia54 Associated with increased healthcare 
utilization 
High telephone encounters52 Increased risk of hospitalization and/or 
emergency room use 
Peripheral eosinophilia55,56  Increased patient charges and healthcare 
utilization 
Obesity in IBD59 Use of lower dosing of IBD related 
medications 
Long-term lipid profiles in IBD60 Dyslipidemia is associated with more 
severe disease 
High healthcare utilization in IBD15 Associated with unemployment, 
psychiatric disease, narcotic use, and 
medical comorbidities. 
Abbreviations: CRP – C reactive protein; IBD – Inflammatory bowel disease 
 
Finally, we have overcome numerous challenges during the development and 
implementation of a longitudinal natural history database (Table 6). An ongoing challenge is the 
quantification of patient follow-up. With natural history data it is difficult to distinguish whether 
a patient did not have an endoscopy because they were lost to follow up, or if they are feeling 
well and did not require endoscopic evaluation. To ensure patients in hypothesis driven studies 
resulting from registry data are only included if they are active in our practice, we organize 
outpatient EMR encounters to quantify a patient’s telephone activity, email exchanges, clinic 
visits, or emergency department use in a calendar year. This data is the backbone of all inclusion 
and exclusion criteria for multi-year studies, and is not routinely accessible in registries unlinked 
from the EMR or cohorts based off of administrative datasets.  
 23 
Table 6. Challenges and solutions in creating and maintaining a registry 
Challenges Solutions 
Data extraction from the 
electronic medical record 
Active and ongoing partnerships with outpatient medical 
record support teams at our local institution. Our local 
partners facilitate data transfer requests. 
Standardization of data capture Patient encounters are standardized, regardless of inclusion 
in the registry. There are standard laboratory orders and 
questionnaires.  
Quantification of patient follow up Participants are considered “active” if they had at least one 
phone call or office visit in the calendar year. 
Complex longitudinal data Initially, patient data is organized by calendar year. Time 
stamped data is available for more complex longitudinal 
data analyses, and time to event analyses. 
Historical data on newly 
consented registry participants 
Each data extraction from the electronic medical record 
provides historical data on each patient from 2009 to date 
of extraction. This overcomes the problem of manual 
filling of historical data as in other non-electronic medical 
record derived registries. 
Recruitment and retention All clinic physicians are actively recruiting IBD patients to 
join the registry. By utilizing the electronic medical record 
as a data source we greatly reduce participant burden and 
increase retention. Physician and staff data entry burden is 
also minimized.  
 
Another facet of data organization that commonly accompanies longitudinal data is the 
identification of study observation intervals. To address this, we prospectively lock our data on a 
calendar year basis. This strategy allows for cross sectional association studies to be repeated on 
each annually locked dataset and provides internal validation for the evaluation of trends over 
time. Previous studies from our group have employed the data to generate prediction models in 
with data from one calendar year, and perform a validation of the prediction model in subsequent 
years.15 The annual trend data is the primary way in which data is curated; however, all raw data 
from the EMR is maintained in a time stamped manner that allows for a granular approach if any 
particular study requires individual data elements. 
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2.4 DISCUSSION 
This paper outlines the design, development, challenges and implementation of an IBD 
research registry at a tertiary care center. We describe successful implementation of an IBD 
research registry generated from the outpatient medical record and linked surveys related to 
patient reported disease activity and quality of life. Given that the majority of IBD patients are 
managed in the outpatient setting, the outpatient registry allows for the examination of real world 
IBD subgroups, treatment patterns, disease trajectories, and clinical effectiveness in a large IBD 
cohort.  
We have made it a research priority to define clinical subtypes of disease that relate to 
poor health outcomes, and have demonstrated that routinely collected patient care data overtime 
can be organized to provide the framework for such studies. The use of routinely collected 
observational patient data from the EMR allows for rapid implementation of research findings at 
other institutions.61 Many studies use point measurements of disease activity indices, quality of 
life scores or biomarkers, but with the registry’s data we are able to evaluate patterns of these 
markers and trends over time which probably reflects disease severity with better accuracy. 
Additionally, we are capturing healthcare data from real world patients and clinical practice, 
which has been advocated by the Institute of Medicine to facilitate rapid comparative 
effectiveness research.62 These large datasets include patients that would be excluded from 
participation in randomized, controlled clinical trials due to comorbid illness or complex disease 
history.38 Thus, research findings generated from the IBD research registry are a closer reflection 
on real world IBD compared to highly controlled trials.  
Registries have been used in the setting of other chronic disorders and rare diseases.63–67 
Despite the utility of research registries in the setting of chronic disorders, there is a lack of 
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publications outlining registry development and implementation of longitudinal medical records 
data, especially in the setting of IBD. Others have described methods of patient identification 
using the medical record, however this approach generates administrative data without the ability 
to contact individuals for current and future study recruitment.68,69 The EMR derived registry 
approach allows identification of patients with unique clinical signatures that may benefit from 
enrollment in research trials. For example, we are in the process of recruiting patients to a 
microbiome research trial based on the extremes of documented gastrointestinal infection, which 
is phenotype data generated from the research registry. Additionally, while we have not yet 
actively pursued these studies, registries can facilitate linkage with other state and national 
databases to enrich the data. Furthermore, using a registry approach we are able to validate 
variables that appear inaccurate and fill in any missing data using the EMR. Generating the 
majority of the data from the EMR also avoids data entry burnout that can restrict the potential of 
registries distinct from the EMR. EMR data pulls also facilitate effortless, unbiased back filling 
of clinical care data that is not routinely available with prospective registries distinct from the 
EMR.  
We have linked the data in the IBD research registry to a variety of validated healthcare 
questionnaires in order to quantify comorbidities in our clinic population. Over time we have 
collected data using an autonomic dysfunction screening questionnaire (COMPASS-31), 
persistent stress questionnaire, an intake depression screen, and a fiber and fat dietary intake 
questionnaire.70–72 Introducing clinical questionnaires into the routine clinical workflow and 
linking the results of these questionnaires to patient data in the registry has resulted in studies 
aimed to validate these questionnaires that have not been used previously in the setting of IBD. 
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Finally, we now have the infrastructure required to examine effectiveness and quality of 
care measures in the setting of IBD, with the development of this registry. New research is 
focusing on the evaluation of the effectiveness of biologic therapies within our patient cohort. 
We are also dedicating research efforts on quality of care metrics including the management of 
surveillance colonoscopies in patients with colonic IBD, infection rates, medication exposure, 
and the frequency and outcomes related to micronutrient repletion.73,74 Furthermore, the 
infrastructure currently afforded by this registry allows application of machine learning 
algorithms to discover patterns in the data. We in the process of testing statistical models that 
could be used to predict poor health outcomes, and are developing exploratory data visualization 
systems to allow clinicians and researchers to observe patient trends over time and rapidly 
identify clinical events of interest. 
In comparison to other population-based cohorts, the EMR based registry approach has 
some advantages. We have learned a great deal from Olmsted County to advance our 
understanding of prevalence and incidence of IBD over time.75 However, the linked census and 
healthcare data is based primarily from diagnosis codes, and achieving data granularity requires 
retrospective chart examination. It is also often cited that, a large percentage of Olmsted County 
inhabitants are also working in healthcare and are highly educated which may make natural 
history findings less generalizable to the larger US population.75 The Ocean State Crohn’s and 
Colitis Registry (OSCCAR), is another registry of a multi-center population that recruited 
incident cases of IBD in Rhode Island up to 6 months from initial diagnosis.76 OSCCAR follows 
patients prospectively at predetermined intervals and has collected extremely valuable data on 
health outcomes, quality of life, and disease activity while having the added benefit biological 
sample collection. While time intervals are consistent across patients these intervals and requires 
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dedicated study personnel to prospectively monitor patients and schedule follow up. Patients in 
the UPMC IBD registry do not need to engage in research outside of their routine clinical care, 
which greatly reduces the burden of research on both the participant and research staff.  
Although the UPMC IBD registry does not capture data at predetermined time points, our aim is 
to capture real-world healthcare utilization data on a patient level, as they require care for 
worsening disease. 
Research registries from Canada have also contributed to our understanding of IBD. The 
Alberta IBD Consortium recently published an influential study on IBD phenotypes and medical 
outcomes using their registry.77 This study employed intensive manual chart review by two 
independent data abstractors with clinical expertise. In the context of our registry, the EMR data 
abstraction methods at the Center for Assistance in Research using eRecord at the University of 
Pittsburgh at UPMC are automated and uniformly applied to all registry participants and may 
reduce errors associated with manual data extraction and interpretation. The Manitoba IBD 
research group has also been influential in advancing our understanding of IBD.78 The Manitoba 
group maintains an open enrollment IBD registry and cohort studies that follow recently 
diagnosed IBD patients.79 In addition to registry data, Manitoba’s IBD related epidemiologic 
studies are strengthened by large administrative datasets that capture universal care. The lack of 
universal care systems in the United States requires creative solutions to track health outcome 
and healthcare utilization data on the majority of our patients. We have detailed one solution to 
this problem through the use of a commonly employed outpatient EMR to serve as the basis of 
real-world data in a longitudinal IBD research registry.  
Despite successful implementation of the IBD research registry, this methodology has 
limitations. The registry is housed at a tertiary care center and may selectively capture highly 
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severe disease. Even with this potential bias, IBD patients in our registry are similar to IBD 
patients seen at other centers, in that they experience unpredictable flares with the clinical goal of 
controlling symptoms and restoring quality of life. Additionally, outpatient data is collected from 
UPMC satellite clinics and allows us to capture routine care that occurs in the community setting 
outside the walls of our tertiary care center. We are also limited in the breadth and accuracy of 
observational data as it is entered into the EMR. To address this, we validate data at the extremes 
to confirm any potential outliers in an effort to improve data accuracy. This limitation applies to 
all forms of research utilizing the EMR as a source of real world data. Finally, with observational 
and interventional research studies there is participation bias of subjects who join the registry. 
We are unable to capture the healthcare states and reasons why persons decline participation in 
the registry.  
We have detailed the methods to develop, implement and utilize a research registry in the 
setting of IBD and ways in which we have overcome challenges associated with real world, 
longitudinal data. Future and current studies utilizing the research registry will be focused on 
better defining IBD phenotypes in an effort to uncover clinical pathways that can be targeted for 
treatment. These studies are designed to bring the practice of Gastroenterology and IBD clinical 
management closer to the ultimate goal of personalized medicine.  
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3.1 INTRODUCTION 
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacilli and the 
etiological agent of antibiotic associated pseudomembranous colitis. Common risk factors for 
community or hospital acquired C. difficile infection (CDI) are comorbid diseases and exposure 
to any class of antibiotics.21,80 Comorbid inflammatory bowel disease (IBD) is considered the 
most significant risk factor for the acquisition of CDI in the community setting.21 Previous 
research has shown that the likelihood of infection is increased by many factors including, but 
not limited to, healthcare system contact, nutritional deficiencies, and antibiotic exposure.80–83 
CDI is an increasingly prevalent infectious complication in the IBD patient population.23,84,85 
CDI in IBD patients is associated with higher rates of hospitalization, surgery, longer hospital 
stays, increased healthcare charges, and, most importantly, an increased mortality.18,20 
Much of what is known about CDI in IBD has been derived from large national databases 
and administrative healthcare data. These data have provided information about increased risks 
of mortality and colectomy in IBD patients with CDI and how these risks have increased over 
time.18,86 However, many of the findings were derived from retrospective samples and 
administrative data, and are unable to account for a patient’s inherent risk of CDI or their disease 
severity prior to infection.87  
We are unaware of any studies that have used a propensity score matching approach to 
generate a control cohort that has similar risk factors of developing CDI in the year prior to 
infection. Our primary aim was to determine the impact of CDI on biomarkers of IBD severity, 
healthcare utilization, and patient reported outcomes compared to a matched cohort based on 
known risk factors for infection. Our secondary aim was to investigate if changes of healthcare 
utilization patterns continued into the year following infection. We hypothesized that CDI would 
 31 
negatively impact patient outcomes in the acute period of infection and in the long-term follow 
up period. 
3.2 MATERIALS, METHODS AND DESIGN 
3.2.1 Study design and participants 
This study was conducted as a part of the UPMC IBD research registry, which has been 
previously described in detail.88 Briefly, IBD patients are consented and enrolled in a 
prospective, longitudinal, natural history registry, which organizes real world patient care data 
from 2009 to the present time. All data from the registry is derived from the electronic medical 
record and systematically processed and transformed for research.  
In this study, we included all IBD patients in the UPMC IBD registry with a definite 
diagnosis based on standard criteria of ulcerative colitis (UC) or Crohn’s disease (CD) for our 
selection of cases and controls. CDI was defined as any patient with a confirmed molecular 
laboratory diagnosis of Clostridium difficile from 2010 to 2014 calendar years. All confirmed 
molecular diagnoses were assumed to have infection. Participants with CDI also had to have 
clinical follow up, defined as at least one clinic visit or telephone encounter in the 
gastroenterology clinic over the calendar year, in the year prior to infection in order to meet 
inclusion criteria. Controls were selected from the remaining IBD registry participants without a 
history of CDI.  
IBD patients in both the case and control groups were excluded if they had unclassified 
IBD or undefined disease type. To allow capture of data from the year before and year after CDI, 
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IBD patients with CDI occurring in 2009 or 2015 were excluded. CDI cases were also excluded 
if they did not have clinical follow up in the year prior to infection. We did not exclude controls 
who had been tested for infection, or CDI positive participants who had multiple or relapsing 
infections, as this is a feature of CDI in IBD patients.22 The CDI positive cohort includes IBD 
patients with single and multiple positive tests for CDI documented in the medical record. 
3.2.2 Data collection and organization 
All data are prospectively collected as a part of routine healthcare visits in any UPMC 
affiliated hospital or clinic (comprising over 20 hospitals and 500 clinics).88 All IBD related 
healthcare utilization including clinic visits, telephone encounters, hospitalizations, emergency 
room (ER) visits, and IBD related surgeries were derived from the IBD registry and temporally 
organized by calendar year. Healthcare utilization was also quantified by financial charges, 
which includes charge data for all healthcare services including, but not limited to, 
gastrointestinal care. Financial charges include both inpatient and outpatient charges, but do not 
include pharmacy charges as prescription charges independent of the UPMC system. Labs were 
ordered as a part of routine care as deemed appropriate by providers, therefore, laboratory 
biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and 
vitamin D and B-12 deficiencies were organized by calendar year and dichotomized as normal or 
abnormal based on local laboratory standards. All outpatient electronic prescriptions were 
organized annually for each patient. Patients were designated as having exposure to the 
medication if they had one or more prescriptions within the calendar year. Antibiotics only 
included systemic exposure. Systemic antibiotics with the exception of vancomycin and 
fidaxomicin were analyzed as a separate category. Within the systemic antibiotics category we 
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looked at the subgroup of patients prescribed metronidazole, as it is indicated in the setting of 
CDI. However, vancomycin and fidaxomicin were analyzed alone as a separate antibiotics 
category, as their primary indications are for CDI.  
Patient reported disease activity and quality of life (QOL) metrics were collected during 
clinical visits to the UPMC Digestive Disorders Clinic as a part of routine care, and entered into 
the electronic medical record. QOL was measured by the Short Inflammatory Bowel Disease 
Questionnaire (SIBDQ).42 Disease activity was measured by the Harvey Bradshaw Index (HBI) 
for CD and Ulcerative Colitis Activity Index (UCAI) for UC.43,44 “Active disease” was defined 
as annual mean UCAI score ≥4 or annual mean HBI scores ≥5 during the study period. Disease 
phenotypic characterization was performed in both CD and UC patients using the Montreal 
Classification at initial presentation.51  
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Figure 2. Schematic of propensity score matching. 
Repeated nearest neighbor propensity score matching by year without replacement. 
3.2.3 Propensity score matching 
To build a comparable control cohort at baseline we utilized nearest neighbor propensity 
score matching.89 We generated the propensity score for CDI with the covariates listed in Table 
7, using logistic regression. The propensity score is considered the calculated “likelihood” of 
infection given a patient’s particular set of covariates.90 All covariates were chosen from 
hypothesis driven clinical parameters that may influence a patient’s risk for CDI. Most 
importantly we included all encounters with the healthcare system and antibiotic exposures in the 
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year prior to infection, which have been implicated in risk for infection.80,81 We also included all 
antibiotic exposures in the year prior to infection, age, and vitamin D deficiency, all which have 
been linked to risk of infection.23,83 Patients were matched using the protocol outlined in Figure 
2, which features a rolling propensity score matching process over time beginning with study 
participants who had their first CDI event in 2010. Matching was done without replacement to 
build a 1:2 (cases:controls) cohort. Any controls matched to cases in previous years were 
excluded from any subsequent control population selection pool. Covariate balance in the year 
prior to infection was examined following matching. 
 
Table 7. Variables included in each propensity score model 
Propensity Score Model Covariates Variable type 
Demographics and disease characteristics  
Age Continuous 
Gender Dichotomous 
Disease type (ulcerative colitis vs. Crohn’s disease) Dichotomous 
Years of disease Continuous* 
Colonic disease by Montreal Classification51 Dichotomous* 
Follow up during the year of infection Dichotomous 
Medication exposure in the year prior to infection 
Biologics Dichotomous 
Immunomodulators Dichotomous 
Prednisone Dichotomous 
5-aminosalicylic acid Dichotomous 
Proton pump inhibitor Dichotomous 
Any systemic antibiotic exposure Dichotomous 
Number of systemic antibiotic exposures Continuous 
Clostridium difficile associated antibiotic exposure† Dichotomous 
Biomarkers of disease severity in the year prior to infection 
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Abnormal C-reactive protein Dichotomous 
Abnormal erythrocyte sedimentation rate Dichotomous 
Low vitamin D (<40 ng/mL) Dichotomous 
Low vitamin B12 (<300 pg/mL) Dichotomous 
Healthcare utilization and healthcare contacts in the year prior to infection 
Clinic visits Continuous 
Number of emergency room visits Continuous 
Number of hospital admissions Continuous 
Number of surgeries Continuous 
Number of endoscopies Continuous 
Number of radiologic procedures§  Continuous 
* Any missing values were matched with dummy variables to characterize missing values.  
† Clostridium difficile associated antibiotics include vancomycin and fidaxomicin. 
‡ Having been tested for Clostridium difficile was removed from all propensity score models due 
to perfect prediction of cases.   
§  Radiologic procedures include all computerized tomography and magnetic resonance imaging 
scans, ultrasounds, and X-rays. 
 
3.2.4 Statistical analysis 
We used chi-square analyses for categorical variables, Student’s t-test for normally 
distributed continuous variables, and the Wilcoxon rank-sum test for nonparametric continuous 
variables to assess differences and balance between groups at baseline. To account for matching, 
outcomes in the year of infection and year after infection were assessed using conditional logistic 
regression for binary outcomes, and fixed effects regression for continuous variables. Counts of 
healthcare utilization (hospitalizations, ER visits, telephone calls, clinic visits, radiologic 
procedures, endoscopies) were initially evaluated using fixed effects Poisson regression and 
significance was ultimately reported using conditional negative binomial regression due to over 
dispersion of zeros. Financial charges were transformed to natural log for normality prior to 
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regression. All statistical tests were evaluated with an alpha = 0.05, and were completed in 
StataSE (v.14, StataCorp, College Station, TX). 
3.2.5 Ethical Considerations 
All participants were enrolled in the IBD Research Registry using informed consent. The 
IBD Research Registry (Protocol #0309054) and the current analysis (Protocol #15010214) were 
both approved by the University of Pittsburgh Institutional Review Board. All authors had access 
to the study data and reviewed and approved the final manuscript. 
3.3 RESULTS 
A total of 198 patients (66 CDI, 132 matched controls) were included (56.6% female; 
60.1% CD, 39.9% UC) (Table 8). Infection and control groups did not significantly differ in 
terms of baseline disease characteristics in the year prior to infection for all available metrics 
(Table 9). Study groups did not differ in regard to contact with the healthcare system including 
hospitalizations, ER visits, endoscopies, radiologic studies, clinic visits, and total financial 
charges. Additionally, the groups did not differ in terms of the proportion of patients who were 
exposed to antibiotics or the number of times they were prescribed antibiotics (Table 9).  
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Table 8. Baseline demographics of inflammatory bowel disease patients included in the study 
  Infection Status  
 
Total Study 
Population 
n= 198 
Clostridium 
difficile positive 
n= 66 
Controls 
n= 132 p-value 
Age (mean years ± SD)* 45.4 ± 15.2 44.3 ± 14.8 45.9 ± 15.5 0.486 
Female, (n, %) 112 (56.6) 34 (51.5) 78 (59.1) 0.311 
Race/Ethnicity, (n, %)     
Caucasian 190 (96.5) 62 (93.9) 128 (97.7) 
0.249 Black 6 (3.1) 3 (4.6) 3 (2.3) 
Other or unknown 1 (0.5) 1 (1.5) 0 (0.0) 
Hispanic/Latino 0 (0.0) 0 (0.0) 0 (0.0) 1.00 
Marital Status, (n, %)     
Married or significant other 120 (60.6) 41 (62.1) 79 (59.9) 
0.447 
Single 58 (29.3) 21 (31.8) 37 (28.0) 
Divorced, widowed, separated 17 (8.6) 4 (6.1) 13 (9.9) 
Unknown 3 (1.5) 0 (0.0) 3 (2.3) 
Employment status (n, %)     
Full time or self-employed 103 (52.0) 36 (54.6) 67 (50.8) 
0.937 
Full time student 12 (6.1) 5 (7.6) 7 (5.3) 
Part-time 7 (3.5) 2 (3.0) 5 (3.8) 
Retired 17 (8.6) 6 (9.1) 11 (8.3) 
Not employed 43 (21.7) 13 (19.7) 30 (22.7) 
Unknown 16 (8.1) 4 (6.1) 12 (9.1) 
SD - standard deviation; *Age of study participants as of January 1, 2015.  
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Table 9. Baseline disease characteristics from the year prior to infection 
  Infection Status  
 Total  n= 198 
CDI positive 
n= 66 
Controls 
n= 132 p-value 
Disease category (n, %)     
Crohn’s disease 119 (60.1) 41 (62.1) 78 (59.1) 0.681 Ulcerative colitis 79 (39.9) 25 (37.9) 54 (40.9) 
Disease characteristics51     
Crohn’s disease location, n=98     
Ileal (L1) 
Colonic (L2) 
Ileocolonic (L3) 
Upper GI (L4) 
26 (26.5) 
31 (31.6) 
44 (44.9) 
4 (4.1) 
7 (20.6) 
9 (26.5) 
18 (52.9) 
3 (8.8) 
19 (29.7) 
22 (34.4) 
26 (40.6) 
1 (1.6) 
0.331 
0.423 
0.243 
0.084 
Crohn’s disease behavior, n=98     
Inflammatory (B1) 
Stricturing (B2) 
Penetrating (B3) 
50 (51.0) 
38 (38.8) 
20 (20.4) 
14 (41.2) 
17 (50.0) 
7 (20.6) 
36 (56.3) 
21 (32.8) 
13 (20.3) 
0.155 
0.096 
0.974 
Perianal disease, n=98 21 (21.4) 6 (17.7) 15 (23.4) 0.506 
Ulcerative colitis extent, n=68     
Proctitis (E1) 
Left-Sided (E2) 
Extensive (E3) 
4 (5.9) 
18 (26.5) 
49 (72.1) 
2 (9.5) 
4 (19.1) 
17 (81.0) 
2 (4.3) 
14 (29.8) 
32 (68.1) 
0.394 
0.354 
0.275 
History of IBD related surgery*  62 (31.3) 18 (27.3) 44 (33.3) 0.386 
Biomarkers of severity (n, %)†     
Elevated CRP 89 (45.0) 30 (45.5) 59 (44.7) 0.920 
Elevated ESR 70 (35.4) 24 (36.4) 46 (34.9) 0.833 
Low Vitamin D (<40 ng/mL) 88 (44.4) 31 (47.0) 57 (43.2) 0.613 
Low B-12 (<300 pg/mL) 37 (18.69) 12 (18.2) 25 (18.9) 0.897 
Medication use (n, %)†     
Immunomodulators 45 (22.7) 15 (22.7) 30 (22.7) 1.00 
Biologics 66 (33.3) 23 (34.9) 43 (32.6) 0.749 
Systemic steroids 81 (40.9) 132 (43.9) 52 (39.4) 0.540 
5-aminosalicylic acids 55 (27.8) 16 (24.2) 39 (29.6) 0.432 
Systemic Antibiotics 107 (54.0) 37 (56.1) 70 (53.0) 0.687 
Metronidazole  44 (22.2) 14 (21.2) 30 (22.7) 0.809 
Vancomycin 35 (17.7) 11 (16.7) 24 (18.2) 0.792 
Average Total SIBDQ, n=145 
(median, [IQR]) 
46 [21.5] 45.7 [18.8] 47 [21.7] 0.273 
Disease activity metrics 
(median, [IQR]) 
    
HBI, n=96 5.0 [6.1] 5.0 [9.5] 5.0 [4.7] 0.860 
 40 
UCAI, n=61 5.0 [8.0] 6.5 [10.0] 4.2 [8.0] 0.147 
Healthcare utilization, (median, [IQR])     
Emergency room visits 0.0 [2.0] 1.0 [3.0] 0.0 [2] 0.075 
Hospitalizations 0.0 [2.0] 0.0 [2.0] 0.0 [2.0] 0.427 
Surgeries, (n, %) 29 (14.7) 10 (15.2) 19 (14.4) 0.887 
Radiologic studies 2.0 [6.0] 3.0 [5.0] 2.0 [6.0] 0.332 
Clinic visits 2.0 [3.0] 2.0 [3.0] 2.0 [2.0] 0.172 
Telephone calls 5.0 [7.0] 5.0 [8.0] 5.0 [7.0] 0.792 
Financial charges ($)  6984.75  [118713.10] 
14462.00   
[125282.00] 
5990.00 
[112014.30] 0.290 
Abbreviations: SIBDQ, short inflammatory bowel disease questionnaire; IBD, inflammatory 
bowel disease; GI, gastrointestinal; IQR, interquartile range; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; HBI, Harvey-Bradshaw Index; UCAI, ulcerative colitis activity 
index. 
* History of any gastrointestinal surgery prior to 2009. 
† Immunomodulators include 6-mercaptopurine, azathioprine, methotrexate. Biologics include 
anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab), anti-integrin 
therapy (vedolizumab and natalizumab). Biologics include all anti-tumor necrosis factor agents 
and anti-integrin therapies. Systemic antibiotics include all systemic antibiotic exposure, 
excluding vancomycin and fidaxomicin. 
 
3.3.1 Year of infection 
In the year of CDI, follow up occurred in 93.4% (n=185) of the cohort, and rates of 
follow up did not differ between infection and control groups (95.5% CDI vs. 92.4% controls). 
Having CDI was significantly associated with increased medication exposure including steroids 
(49.2% CDI vs. 28.7% controls, p=0.005) systemic antibiotics (excluding vancomycin) (90.5% 
CDI vs. 50.8% controls, p<0.001), and vancomycin exposure (73.0% CDI vs. 12.3% controls, 
p<0.001) (Table 10). Neither group had any exposure to fidaxomicin or fecal microbiota 
transplantation. The CDI group also had a greater total number of antibiotic prescriptions 
(median: 3 CDI vs. 1 controls, p<0.001). The two groups did not differ in their exposure to 5-
aminosalicylic acids, immunomodulators, or biologic medications (Table 10).  
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Infection was also significantly associated with elevated inflammatory biomarkers 
including CRP (58.7% CDI vs. 32.0% controls, p=0.002) and ESR (41.3% CDI vs. 18.0% 
controls, p=0.002), low vitamin D (p=0.001), and low vitamin B-12 (p=0.02) (Table 10). Using 
patient reported metrics, infection was associated with lower QOL scores (p=0.003) and self 
reported active disease (p=0.02) (Table 10).  
 
Table 10. Disease severity, medication exposure and healthcare utilization from the year of 
Clostridium difficile infection 
  Infection Status  
 Total  n=185 
CDI positive 
n=63 
Controls 
n=122 p-value 
Medication use (n, %)†     
Immunomodulators 45 (24.3) 13 (20.6) 32 (26.2) 0.399 
Biologics 54 (29.2) 19 (30.2) 35 (28.7) 0.812 
Systemic steroids 66 (35.7) 31 (49.2) 35 (28.7) 0.005 
5-aminosalicylic acids 41 (22.2) 17 (27.0) 24 (19.7) 0.355 
Systemic antibiotics 119 (64.3) 57 (90.5) 62 (50.8) <0.001 
Metronidazole  48 (26.0) 27 (42.9) 21 (17.2) <0.001 
Vancomycin 61 (33.0) 46 (73.0) 15 (12.3) <0.001 
Biomarkers of severity (n, %)     
Elevated CRP 76 (40.1) 37 (58.7) 39 (32.0) 0.002 
Elevated ESR 49 (26.0) 26 (41.3) 22 (18.0) 0.002 
Low Vitamin D (<25 ng/mL) 42 (22.7) 24 (38.1) 18 (14.8) 0.001 
Low Vitamin D (<40 ng/mL) 96 (50.3) 42 (66.7) 51 (41.8) 0.001 
Low B-12 (<300 pg/mL) 21 (11.4) 11 (17.5) 10 (8.2) 0.027 
Average Total SIBDQ, n=130 
(median, [IQR]) 
48.3 [20.3] 43.2 [19.9] 53.5 [22.0] 0.003 
Active disease (n, %)* 65 (48.9) 33 (63.5) 32 (39.5) 0.016 
Disease activity metrics, (median, 
[IQR])     
Harvey-Bradshaw Index, n=92 3.5 [5.6] 5.5 [6.5] 2.5 [5.0] 0.006 
UCAI, n=51 5.0 [7.0] 6.2 [7.0] 4.0 [6.0] 0.960 
Healthcare utilization, (median, [IQR])     
Emergency room visits 0.0 [1.0] 0.0 [4.0] 0.0 [1.0] <0.001 
Hospitalizations 0.0 [1.0] 1.0 [4.0] 0.0 [1.0] <0.001 
Surgeries, (n, %) 18 (9.73) 6 (9.52) 12 (9.84) 1.00 
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Radiologic Procedures 1.0 [4.0] 2.0 [5.0] 1.0 [3.0] <0.001 
Endoscopies 1.0 [1.0] 1.0 [1.0] 1.0 [1.0] <0.001 
Clinic visits 2.0 [3.0] 3.0 [3.0] 2.0 [2.0] <0.001 
Telephone calls 5.0 [8.0] 9.0 [12.0] 3.0 [7.0] <0.001 
Financial charges ($) 6805.00  [94059.00] 
28433.88  
[149294.70] 
4989.00 
[65498.25] <0.001 
P-values are bolded if significant, <0.05.  
Abbreviations: SIBDQ – short inflammatory bowel disease questionnaire; IBD – inflammatory 
bowel disease; GI – gastrointestinal; IQR – interquartile range; CRP – C-reactive protein; ESR – 
erythrocyte sedimentation rate; UCAI – ulcerative colitis activity index. 
*Active disease defined as annual mean ulcerative colitis activity index score ≥4 or annual mean 
Harvey-Bradshaw Index scores ≥5 during the study period. 
† Immunomodulators include 6-mercaptopurine, azathioprine, methotrexate. Biologics include 
anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab), anti-integrin 
therapy (vedolizumab and natalizumab). Biologics include all anti-tumor necrosis factor agents 
and anti-integrin therapies. Systemic antibiotics include all systemic antibiotic exposure, 
excluding vancomycin and fidaxomicin. 
 
Patients with CDI experienced significantly increased healthcare utilization across all 
measured metrics except the proportion of patients requiring surgery during the year of infection 
(Table 10). Those with CDI had an increased number of radiographic studies, endoscopies, 
clinic visits, and telephone encounters (all p<0.001). They also had more unplanned care 
including ER visits (mean: 3.7 CDI vs. 1.1 controls, p<0.001) and hospitalization (mean: 2.2 
CDI vs. 0.8 controls, p<0.001). Patients with CDI had increased financial healthcare charges in 
the year of infection (p<0.001) (Table 10). 
3.3.2 Year after infection 
In the year after infection, follow up occurred in 77.8% (n=154) of the original study 
group. The CDI group includes patients with single or multiple positive tests for CDI. CDI 
patients were significantly more likely to follow up in the year after infection (CDI 90.9%; 
controls 71.2%) compared to controls (p=0.003), (Table 11). 
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Those with prior CDI continued to have increased exposure to vancomycin (p<0.001) and 
other systemic antibiotics (p=0.02). Neither group had any exposure to fidaxomicin or fecal 
microbiota transplantation in the year after infection. All other medication exposures including 
biologics, systemic steroids, immunomodulators, and 5-aminosalicyclic acid agents did not differ 
between groups, although exposure to systemic steroids nearly met significance (p=0.07) (Table 
11). In the year following infection, CDI patients continued to have more clinic visits (p=0.02), 
and telephone encounters (p=0.001). CDI patients also had significantly more financial 
healthcare charges in the year after infection (median $51,146.00 CDI vs. $8,120.50 controls, 
p=0.003). However, patient reported disease activity, QOL (p=0.08), and biomarkers of severity 
including ESR and CRP were not significantly different between the two groups. Other metrics 
of healthcare utilization including radiologic studies, endoscopy, surgery, hospitalizations, and 
ER visits were not significantly different (Table 11). 
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Table 11. Risk of future disease severity and healthcare utilization in the year after infection 
  Infection Status  
 Total n=154 
CDI Positive 
n=60 
Controls 
n=94 p-value 
Follow up year after infection, n (%) 154 (77.8) 60 (90.9) 94 (71.2) 0.003 
Biomarkers of Severity     
Elevated CRP 45 (29.2) 18 (30.0) 27 28.7) 0.797 
Elevated ESR 36 (23.4) 16 (26.7) 20 (21.3) 0.328 
Medications† n (%)     
Biologics, n (%) 49 (31.8) 23 (38.3) 26 (27.7) 0.260 
Immunomodulators 49 (31.8) 16 (26.7) 33 (35.1) 0.487 
Prednisone 48 (31.2) 23 (38.3) 25 (26.6) 0.067 
5-aminosalicylic acids 34 (22.1) 15 (25.0) 19 (20.2) 0.490 
Systemic antibiotics 81 (52.6) 39 (65.0) 42 (44.7) 0.023 
Metronidazole 22 (14.3) 8 (13.3) 14 (14.9) 0.931 
Vancomycin 34 (22.1) 23 (38.3) 11 (11.7) 0.001 
Average Total SIBDQ, n=102 
(median, [IQR]) 
49.8 [19.0] 47.0 [22.0] 51.5 [19.5] 0.078 
Disease activity, (median, [IQR])     
HBI (Crohn’s disease), n=73 3.7 [6.0] 4.0 [6.0] 3.0 [5.0] 0.698 
UCAI (Ulcerative colitis), n=39 2.0 [5.0] 3.3 [5.0] 2.0 [5.8] 0.931 
Healthcare utilization, (median [IQR])     
Telephone calls  4.0 [7.0] 5.5 [8.5]  3.0 [5.0] 0.001 
Office visits 2.0 [2.0] 2.0 [3.0]  1.0 [1.0] 0.023 
Radiologic procedures 1.0 [4.0] 1.0 [7.0]  1.0 [4.0] 0.552 
Endoscopies 1.0 [1.0] 1.0 [1.0] 1.0 [1.0] 0.874 
Surgery, n (%) 8 (5.2) 4 (6.7) 4 (4.3) 0.778 
Hospitalizations 0.0 [1.0] 0.0 [2.0] 0.0 [0.0] 0.400 
Emergency room visits 0.0 [2.0] 0.0 [3.0] 0.0 [1.0] 0.087 
Financial charges ($) 11309.00 [98577.50] 
51146.00 
[182517.00] 
8120.50 
[63850.25] 0.001 
Bolded p-values are statistically significant (p<0.05) 
Abbreviations: SIBDQ, short inflammatory bowel disease questionnaire; CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; IBD, inflammatory bowel disease; CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; HBI, Harvey Bradshaw Index; UCAI, Ulcerative 
colitis activity index; IQR, interquartile range 
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† Immunomodulators include 6-mercaptopurine, azathioprine, methotrexate. Biologics include 
anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab), anti-integrin 
therapy (vedolizumab and natalizumab). Biologics include all anti-tumor necrosis factor agents 
and anti-integrin therapies. Systemic antibiotics include all systemic antibiotic exposure, 
excluding vancomycin and fidaxomicin. 
 
3.3.3 Year after infection, excluding patients with multiple infections 
Of the 60 CDI patients who had follow up in the year after infection, there were 18 
patients (30%) who had more than one CDI infection documented with molecular testing during 
their participation in the UPMC IBD research registry. We performed a subgroup analysis of the 
patients who followed up the year after infection and did not have multiple documented 
infections (n=136: 42 CDI, 94 controls). When patients who had more than one documented CDI 
were excluded, we observed that higher exposure to vancomycin in the CDI group remained 
significant (33.3% CDI vs. 11.7% controls, p=0.03) in the year after infection. Meanwhile, the 
exposure to all other classes of antibiotics was no longer significantly different (p=0.64) between 
the two groups. 
After excluding those with multiple CDI, we observed that the number of clinic visits 
(median [IQR]: 2 [3] CDI vs. 1 [1] controls) between groups is no longer significantly different 
(p=0.18), but CDI patients continued have significantly more telephone encounters (median 
[IQR]: 5 [8] CDI vs. 3 [5.5] controls, p=0.04) in the year after infection. CDI patients also 
continued to have significantly more healthcare related charges (median [IQR]: $40,865.25 
[$149,684.90] CDI vs. $7,775.08  [$74,816.48] controls, p=0.018), after excluding patients with 
multiple positive CDI molecular tests.  
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3.4 DISCUSSION 
In this propensity score matched analysis of CDI patients compared to controls, 
participants were matched on risk factors for Clostridium difficile in the year prior to infection. 
While groups did not differ at in any measured metrics at baseline, those who developed CDI in 
the following year demonstrated significantly increased biomarkers of inflammation (CRP and 
ESR), increased patient reported metrics of disease severity, increased medication exposure, 
decreased QOL, and significantly increased inpatient and outpatient healthcare utilization 
compared to controls. Interestingly, the increase in healthcare utilization and antibiotic exposure 
extended into the year after infection for patients with CDI. Differences in QOL just failed to 
reach statistical significance in the year after infection. This could be due to the statistically 
lower follow up in the control group in the year after infection. The poor follow up in the control 
group results in fewer QOL scores completed from patients who are likely feeling well. Overall, 
the findings suggest CDI has a lasting and measureable impact on IBD patients beyond the acute 
care period. 
Previous research has shown that CDI in IBD is associated with systemic inflammation 
and disease activity, which we validated in this propensity matched cohort study.91,92 In addition 
to association with measures of disease severity, we observed that patients with CDI were more 
frequently prescribed and exposed to systemic steroids during the year of infection. This could 
be due to worsening of symptoms initially thought to be a flare of IBD and may have been 
attributable to infection, or CDI that precipitates an IBD flare. These data highlight the difficulty 
of diagnosis and importance of proper management of CDI in the setting of IBD, as both 
infection and disease flare present with similar symptoms of elevated inflammatory biomarkers 
and diarrhea.  
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A recent meta-analysis demonstrated that CDI is a significant risk factor for colectomy in 
patients with IBD.86 Our study failed to find differences in the proportion of patients requiring 
surgery in the year of infection and the year after. This could be due to the baseline matching, 
which selected for a severe disease cohort from the outset, placing both groups at higher risk for 
surgery than the general IBD population. This is supported by the fact that a third of patients had 
a history IBD related surgery prior to study enrollment, and around 15% of patients had surgery 
in the year prior to infection. In the year of infection approximately 9% of patients had an IBD 
related surgery, and this was similar between groups. Other reasons for the lack of surgical 
endpoints in this study includes the relatively small cohort of patients, and that we did not 
exclude patients who had prior surgery or colectomy.  
In this study, we included participants who had multiple positive molecular tests for CDI. 
Recurrent infection is a significant and important feature of CDI in the setting of IBD that we 
hoped to characterize with longitudinal observational data. Additionally, many IBD patients are 
treated empirically without repeat molecular testing due to the high likelihood that persistent 
symptoms represent CDI recurrence in the setting of IBD. Similar to other studies, we observed 
approximately one-third of patients experience repeat infection confirmed with molecular 
testing.22 To ensure that patients with documented recurrent infection were not influencing the 
results of the statistically significant parameters, we repeated the analysis excluding this fraction 
of patients and found similar significant results in relation to increased vancomycin antibiotic 
exposure, increased telephone encounters possibly due to continuing empiric therapy, and 
increased financial charges which serves as an all-encompassing healthcare utilization metric. 
However, the differences in the number of clinic visits were no longer statistically significant.  
 48 
This study was performed at a tertiary care center, and therefore may not be generalizable 
to patients in the community setting. However, the UPMC IBD Registry collects all data from 
the electronic medical record, which includes over 22 different hospitals and 500 clinics in the 
surrounding community. This analysis is restricted to only those patients who are enrolled in the 
UPMC IBD Research registry, and is therefore subject to participation bias. Given the strict 
inclusion criteria of requiring clinical follow-up in the year prior to infection, we may have 
missed valuable data on patients initially presenting to our tertiary care clinic for worsening 
disease that could be attributed to CDI, or were diagnosed with CDI on their first visit to the 
Digestive Disorders Center. We recognize that there is a testing bias, as only those initially tested 
for CDI due to clinical suspicion were included in our CDI cohort. Choice of methodology for 
testing was not standardized among providers and not captured in the registry data; therefore, we 
do not have detailed data regarding colonization as compared to infection. The size of our cohort 
is also relatively small, including only 66 patients with CDI; therefore, some of our measured 
outcomes in the year after infection may have lacked statistical power due to low sample size. 
Despite the small size of our study cohort, we were able to observe highly significant differences 
between the matched groups in the year of infection and the year after infection.  
This is the first propensity score matched analysis of a CDI cohort in the setting of IBD. 
This approach helps to alleviate many of the caveats associated with a random sample, as those 
who have a history of infection may be inherently different due to risk factors associated with 
infection. These data are prospectively derived from the electronic medical record and represents 
real world care of IBD patients, as it is not collected under the standardized setting of a clinical 
trial. The analysis of real world data brings us closer to understanding typical care patterns and 
the true IBD patient experience of CDI.  
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In conclusion, CDI negatively impacts the clinical course of IBD in the year of infection, 
and also has lasting and measurable effects. CDI results in increased IBD activity, elevated 
biomarkers of inflammation, poor health- related QOL, and increased healthcare utilization 
during the year of infection, some of which extends into the year after infection. Given the 
dramatic impact of CDI on IBD, future studies evaluating treatment strategies of CDI in IBD are 
needed.  
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4.1 INTRODUCTION 
Inflammatory bowel disease (IBD) is a complex immune mediated disorder including 
Crohn’s disease (CD) and ulcerative colitis (UC).1 Extraintestinal manifestations of IBD occur in 
up to 50% patients and can involve almost every organ system.8,93,94 Dermatologic complications 
are one of the most common.24 Between 22-75% of CD patients, and 5-11% of UC patients are 
thought to have mucocutaneous findings associated with IBD.25  
There is a range of associated cutaneous findings in IBD. Certain cutaneous 
manifestations mirror disease activity, while others occur at random.94,95 Hallmark dermatologic 
manifestations of IBD include pyoderma gangrenosum, and erythema nodosum, both of which 
are reactive skin lesions.94 Medication exposures can increase the risk of cutaneous findings in 
IBD including adverse psoriaform skin lesions in patients receiving anti-tumor necrosis factor 
(anti-TNF) therapy.8,96 Melanoma and non-melanoma skin cancer (NMSC) risk are increased in 
IBD.9,26,97 While there are studies suggesting biologics may further increase the risk of 
melanoma in immunosuppressed populations, including IBD,28–30 the American College of 
Gastroenterology (ACG) preventive care guidelines for IBD patients suggest melanoma 
screening skin exams for UC and CD patients, independent of biologic therapy.98 There are also 
data to support the increased risk of NMSC among IBD patients on immunomodulator 
therapy;27,28,31,99–101 therefore, the ACG guidelines similarly recommend patients on thiopurines 
(6-mercaptopurine or azathioprine) obtain a skin cancer-screening exam due to increased risk of 
NMSC.98 Finally, the Crohn’s and Colitis Foundation (CCFA) preventive guidelines suggest 
anyone on systemic immunosuppression (azathioprine, 6-mercaptopurine, methotrexate, anti-
TNFs, anti-IL-12/23) undergo annual skin cancer screening.98  
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Total body skin exams to detect skin cancer remain relatively infrequent among the 
general population in the United States. Studies estimate only 8-15% of the general population 
report having a recent skin exam by a physician.102,103 These estimates may not reflect the rates 
of preventive care skin exams among IBD patients who are recommended for screening and 
frequently obtain coordinated care from specialists. Despite the extensive literature outlining the 
comorbid skin conditions associated with disease activity, heightened risk of skin cancer, and the 
high percentage of patients that are likely to experience dermatologic problems, it is uncertain 
how many IBD patients are actively seeking dermatologic care, and for what reasons. The aims 
of this study were to define the rate of dermatologic care in IBD patients, identify the reasons for 
dermatology visits with a focus on skin cancer screening, and determine factors associated with 
dermatology use.  
4.2 METHODS 
4.2.1 Study population 
This study was conducted at a single tertiary referral center. All subjects included in this 
study are a part of the University of Pittsburgh Medical Center (UPMC) IBD research registry. 
The data collection methods and variables associated with the registry have been previously 
described in detail.88 Briefly, clinical care data from the outpatient electronic medical record are 
prospectively collected, exported and organized for the purposes of research. The registry 
captures outpatient encounters across all specialties that utilize the outpatient electronic medical 
record within the UPMC healthcare system. Encounter specific data, including primary diagnosis 
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codes, are also curated and organized at the visit and patient level. Registry participants were 
eligible for inclusion in this study if they were consented and enrolled in the UPMC IBD 
research registry, had a confirmed diagnosis of CD or UC, using standard diagnostic criteria, and 
had at least one in-person clinic visit in the digestive clinic from 2010-2016. Patients were 
excluded from this study if they did not have an established diagnosis of IBD, or they were not 
seen in the digestive clinic at any point between 2010-2016.  
4.2.2 Clinical data collection 
4.2.2.1 IBD related clinical information 
IBD specific clinical data include disease type (CD or UC), duration of the disease, and 
extent and behavior at diagnosis using the Montreal classification.51 Medication exposures were 
assessed using prescriptions and categorized as exposure per year. Medication categories 
consisted of immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), biologics (anti-
TNF, anti-interleukin-12/23, and anti-integrin), 5-aminosalyslyic acid agents, systemic steroids, 
and topical steroids. Healthcare utilization was quantified using the total number of emergency 
room (ER) visits, hospital admissions, IBD clinic visits, telephone calls, and the need for an 
IBD-related surgery over the study period. We dichotomized certain healthcare utilization 
metrics as “ever occurring” over the study period for meaningful interpretation (surgery, 
hospitalization, and ER visit).  
We assessed biomarkers of inflammation including C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR). ESR and CRP were transformed into annual dichotomous 
variables if they were elevated using local laboratory reference values, and were determined as 
“ever-abnormal” over the study period. Disease-related clinical activity scores were 
 54 
prospectively collected at outpatient visits using the Harvey-Bradshaw Index (HBI) for CD and 
ulcerative colitis activity index (UCAI) for UC.43,44 Active disease was defined as mean UCAI 
score ≥4 or mean HBI scores ≥5 during the study period. The short inflammatory bowel disease 
questionnaire (SIBDQ) was collected at outpatient visits to estimate participants’ health-related 
quality of life.42 Mean disease activity and quality of life scores were calculated over the entire 
study period.  
4.2.2.2 Dermatology utilization data 
From those eligible for the study, we captured all patient encounters (clinic visits, 
procedural visits, emails, and telephone encounters) that were completed at a dermatology clinic 
or were associated with a dermatology practice group in the UPMC system from 2010-2016. We 
organized in-person dermatology patient encounters (clinic visits and procedural visits) by year 
and further classified reasons for care into categories (Appendix A, Table 19). The grouping 
was based on clinical indications as defined by primary diagnosis codes associated with each 
visit or procedure. A practicing dermatologist (LF) verified the final categories. We then 
determined the frequency of dermatology care by indication for each calendar year and overall 
from 2010-2016.  
To determine the proportion of patients actively seeking dermatologic care, we divided 
the number of IBD patients with dermatologic visits (clinic or procedural) by the number of IBD 
patients with clinical follow up in the digestive clinic. Clinical follow up was used to estimate of 
the number of IBD patients actively seeking gastrointestinal/specialty care, and defined as any 
clinic visit within a calendar year. We excluded telephone calls as a source of clinical follow up 
as we assumed only in-person visits or procedures would provide appropriate interaction time 
between provider and patient to discuss preventive care guidelines.  
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To determine the proportion of patients obtaining skin cancer screening as their primary 
reason for visiting dermatology, we considered any outpatient visit or procedure involving the 
primary diagnosis codes within the category of “screening”, outlined in Appendix A, Table 19, 
as involving screening for skin malignancy. We used this proxy as a conservative estimate of 
skin cancer screening including only total body skin exams in which clinicians screened for skin 
cancer, so the results were not inflated due to incidental findings of skin cancers or spot checks 
that occur during other visits, such as a follow up visit for psoriasis or dermatitis. Prior validation 
of this approach within our health system found this ICD9/ICD10 classification methodology 
may miss approximately 20% of total body skin exams (data unpublished), which we explored in 
sensitivity analyses. From this definition of total body skin exams, we determined the number of 
unique individuals with skin cancer screening during the calendar year and calculated the 
proportion of patients with screening compared to the number of patients at the IBD clinic and 
each particular high-risk subgroup. 
4.2.3 Definition of high-risk subgroups for skin cancer screening 
Given the preventive care guidelines in IBD, we evaluated how many patients were 
recommended for screening each year according to ACG or CCFA guidelines.98,104 The ACG 
recommends all UC and CD patients undergo skin cancer screening for melanoma regardless of 
medication exposures, which we considered to be all patients with in-person follow up in the 
digestive clinic.98 The ACG also recommends patients on thiopurines undergo screening for 
NMSC, particularly those over age 50.98 This population was defined as any patient within the 
digestive clinic cohort with 6-mercaptopurine or azathioprine exposure (prescription), who was 
over 50 years old as of January 1st of the associated calendar year. Finally, the CCFA 
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recommends annual screening for skin cancer for all IBD patients on any immunosuppression.104 
This population was defined as any patient within the digestive clinic cohort exposed to 
azathioprine, 6-mercaptopurine, methotrexate, anti-TNFs, ant-integrin, and/or anti-interleukin-
12/23 agents within the calendar year. Within each of the defined high-risk subgroups we 
determined the proportion of patients who were seen by dermatology, and those with primary 
diagnosis codes indicating skin cancer screening as the primary reason for their visit. 
4.2.4 Capturing skin cancer diagnoses 
IBD patients with concurrent diagnosis of melanoma and NMSC were identified through 
primary visit diagnoses codes at dermatology visits and/or pathology diagnoses of melanoma, 
squamous cell carcinoma, or basal cell carcinoma. All skin cancer diagnoses identified through 
medical records and pathology data extraction were confirmed using manual chart review.  
4.2.5 Statistical analysis 
Descriptive statistics of IBD patients with and without a history of dermatologic care 
were calculated as means and standard deviations for normally distributed variables, and median 
and interquartile range for nonparametric variables. Categorical variables and the fraction of 
patients obtaining care were presented as proportions. Proportions were averaged over seven 
years and reported with the 95% confidence interval. Incidence rates of melanoma and NMSC 
were calculated as the number of cases per total person-years of in-person follow up in the 
digestive clinic. To compare between dermatology and no-dermatology groups we used the 
Student’s t-test for normally distributed continuous variables, the Wilcoxon rank-sum test for 
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non-parametric continuous variables, and categorical variables were compared between groups 
using the Chi-squared test. To evaluate IBD factors associated with dermatologic care we used 
univariable and multivariable logistic regression analysis. Hypothesis driven covariates, and 
those p-value <0.10 on univariable analysis were included in multivariable logistic regression 
models. All statistical tests used an alpha <0.05. 
4.2.6 Ethical considerations 
The UPMC IBD research registry (Protocol # 0309054) and this particular study 
(Protocol #PRO17040311) were approved by the University of Pittsburgh Institutional Review 
Board. 
4.3 RESULTS 
4.3.1 Study cohort 
There were 2127 IBD patients in the IBD registry from 2010-2016 that were eligible for 
this study and evaluated for the use of dermatologic care. Of these, 452 (21.3%) IBD patients 
obtained dermatologic care from January 1, 2010 – December 31, 2016. The majority of IBD 
patients seeking dermatologic care were female (55.5%), with a mean age of 46.1 ± 14.9 years 
(Table 12). Over half of the patients were employed, married, were Caucasian, and 21% of 
patients were active smokers (Table 12). Five percent of the cohort had a family history of skin 
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cancer (NMSC and/or melanoma), which was significantly increased in the cohort using 
dermatology (18.1% vs. 1.9%) (Table 12). 
  
Table 12. Dermatology study cohort demographics 
  Dermatology utilization 
 
Total  
n= 2,127 
Dermatology 
n= 452 
No Dermatology 
n= 1675 p-value 
Age (mean years ± SD)* 46.1 ± 15.3 46.1 ± 14.9 46.1 ± 15.4 0.981 
Female, n (%) 1,108 (52.1) 251 (55.5) 857 (51.2) 0.099 
Race/Ethnicity, n (%)     
Caucasian 1989 (94.3) 423 (93.8) 1,566 (94.4) 
0.109 
Black 51 (2.4) 14 (3.1) 37 (2.2) 
Other, unknown, or 
not specified 
62 (2.9) 10 (2.2) 52 (3.1) 
Hispanic/Latino 8 (0.4) 4 (0.9) 4 (0.2) 
Marital Status, n (%)     
Married  1,180 (55.5) 252 (55.8) 928 (55.5) 
0.131 
Single 739 (34.8) 166 (36.7) 573 (34.3) 
Divorced, widowed, 
separated 
175 (8.2) 32 (7.1) 143 (8.6) 
Unknown 31 (1.5) 2 (0.4) 29 (1.73) 
Employment status (n, %)     
Full time or self-
employed 
1080 (51.2) 251 (55.5) 829 (50.1) 
0.001 
Full or part time 
student 
161 (7.6) 39 (8.6) 122 (7.4) 
Part-time 50 (2.4) 13 (2.9) 37 (2.2) 
Retired 173 (8.2) 36 (8.0) 137 (8.3) 
Not employed 401 (19.0) 87 (19.3) 314 (19.0) 
Unknown 243 (11.5) 26 (5.6) 217 (13.1) 
Smoking status (n, %)     
Current use 452 (21.4) 98 (21.7) 354 (21.3) 
0.983 Former use 406 (19.2) 86 (19.0) 320 (19.3) 
Never  1,256 (59.4) 268 (59.3) 988 (59.5) 
Family history of skin 
cancer (n, %) 114 (5.5) 82 (18.1) 32 (1.9) <0.001 
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4.3.2 Dermatology healthcare utilization 
The 452 IBD patients were responsible for 1633 dermatology office visits, 278 
procedural visits, 1108 telephone encounters, and 127 patient emails between the years 2010 and 
2016. Patients ranged from 1 to 44 procedure or office visits over the study period, with a 
median of 2 total visits over the 7-year study period. The study participant with 44 in-person 
visits was being actively treated for vitiligo, which resulted in frequent treatments and follow up. 
Among the patients who saw dermatology, median number of dermatology visits per patient in a 
single calendar year was 1.0 visit. 
4.3.3 Indications for dermatologic care 
The indications for care, as determined by primary diagnosis codes, remained relatively 
consistent each year (Appendix A, Table 20). The most frequent indication for office or 
procedure visits each year was “contact dermatitis or dermatitis”. While other indications 
fluctuated slightly from year to year, the top categories included: contact dermatitis; acneiform 
eruptions; neoplasm of uncertain behavior or unspecified; benign neoplasm; actinic keratosis and 
solar skin aging; and psoriasis (Appendix A, Table 20). We also evaluated the percentage of 
patients seeking care for known extraintestinal manifestations of IBD including primary 
diagnosis codes of pyoderma gangrenosum, erythema nodosum, hidradenitis suppurativa, and 
IBD (details in Appendix A, Table 19). The proportion of dermatologic visits in the IBD 
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category varied between a minimum of 1.1% to a maximum of 10.3% of all dermatologic visits 
by IBD patients per year, averaging a total of 4.1% (95%CI: 1.23-6.9) of visits per year.   
4.3.4 Annual rate of dermatology use in IBD patients 
The proportion of IBD patients seeking dermatologic care compared to those with an in-
person visit in the IBD clinic ranged from 3.6% – 10.8%, with an average of 8.3%, over the 
seven-year study period (Figure 3, Table 13). Similar trends were observed in the CCFA and 
ACG high-risk subgroups (Figure 3), with 8.6% and 10.9% of patients visiting dermatology 
each year, respectively (Table 13). 
Table 13. Proportion of inflammatory bowel disease patients with dermatologic care and skin 
cancer screening per year 
 Mean 95% CI 
Total IBD patients (n=2127)   
IBD Patients with dermatologic visit per year, (n) * 132.7 [101.3, 164.1] 
IBD Patients with TBSE, (n) † 12.4 [6.8, 18.1] 
IBD patients with digestive visit, (n) 1089.4 [951.6, 12227.3] 
Proportion with dermatologic visit (%)* 8.3 [6.1, 10.6] 
Proportion with TBSE (%)† 0.9 [0.3, 1.4] 
IBD patients under CCFA recommendations, (n) 809.9 [692.3, 927.4] 
Proportion with dermatologic visit (%)* 8.6 [6.5, 10.7] 
Proportion with TBSE (%)† 0.8 [0.4, 1.1] 
IBD patients under ACG recommendations, (n) 110.6 [97.9, 123.2] 
Proportion with dermatologic visit (%)* 10.9 [7.1, 14.6] 
Proportion with TBSE (%)† 2.5 [0.4, 4.6] 
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Table 14. Clinical characteristics of inflammatory bowel disease patients with and without a dermatologic 
visit 
  Dermatology Utilization 
 Total Dermatology No Derm p-value 
 n= 2,127 n= 452  n= 1675  
Disease category (n, %)     
Crohn’s disease 1,341 (63.1) 291 (64.4) 1,050 (62.7) 
0.508 
Ulcerative colitis 786 (36.9) 161 (35.6) 635 (37.3) 
Years of disease, (mean ± SD) n=1440 18.9 ± 10.3 20.0 ± 11.5 18.6 ± 10.0 0.037 
Disease characteristics     
Crohn’s disease location, n=1,67     
Ileal (L1) 
Colonic (L2) 
Ileocolonic (L3) 
Upper GI (L4) 
316 (29.6) 
217 (20.3) 
535 (50.2) 
43 (4.0) 
65 (27.0) 
45 (18.7) 
127 (52.7) 
11 (4.6) 
251 (30.4) 
172 (20.8) 
408 (49.5) 
32 (3.9) 
0.307 
0.465 
0.376 
0.632 
Crohn’s disease behavior     
Inflammatory (B1) 
Stricturing (B2) 
Penetrating (B3) 
456 (42.8) 
408 (38.2) 
239 (22.4) 
112 (46.5) 
83 (34.4) 
51 (21.2) 
344 (41.7) 
325 (39.4) 
188 (22.8) 
0.187 
0.168 
0.600 
Perianal disease 193 (18.1) 48 (19.9) 145 (17.6) 0.402 
Ulcerative colitis extent, n=607     
Proctitis (E1) 
Left-Sided (E2) 
Extensive (E3) 
47 (7.7) 
199 (32.8) 
351 (57.8) 
9 (7.1) 
39 (31.0) 
77 (61.1) 
38 (7.9) 
160 (33.3) 
274 (57.0) 
0.777 
0.623 
0.401 
Biomarkers (n, %)     
Elevated CRP, n=1,925 1,063 (55.2) 249 (59.4) 814 (54.1) 0.050 
Elevated ESR, n=1,916 816 (42.6) 208 (49.6) 608 (40.6) 0.001 
Medication use (n, %)†     
Biologics 935 (44.0) 245 (54.2) 690 (41.2) <0.001 
Any immunomodulator 1,177 (55.3) 265 (58.6) 912 (54.5) 0.113 
Thiopurines (6MP + AZA) 947 (44.5) 199 (44.0) 748 (44.7) 0.811 
Methotrexate  326 (15.3) 98 (21.7) 228 (13.6) <0.001 
5-aminosalicylic acids 1,109 (52.1) 244 (54.0) 865 (51.6) 0.377 
Systemic steroids 1,200 (56.4) 319 (70.6) 881 (52.6) <0.001 
Topical steroids 457 (21.5) 277 (61.3) 180 (10.8) <0.001 
Average total SIBDQ, n=1951 (median, IQR) 54.0 [16.9] 54.3 [14.9] 54.0 [17.7] 0.719 
Active disease, n=1,906 (n, %) 652 (34.2) 135 (32.9) 517 (34.6) 0.537 
Healthcare utilization     
Emergency room visit, (n, %) 1,137 (53.5) 315 (69.7) 822 (49.1) <0.001 
Hospitalization, (n, %) 1,075 (50.5) 261 (57.7) 814 (48.6) 0.001 
IBD related surgery, (n, %) 396 (18.6) 92 (20.4) 304 (18.2) 0.285 
Digestive clinic visits, (median, IQR) 6.0 [7.0] 7.0 [9.0] 5.0 [6.0] <0.001 
Digestive clinic telephone encounters, 
(median, IQR) 13.0 [19.0] 17.0 [27.0] 12.0 [18.0] <0.001 
 62 
 
4.3.5 IBD characteristics associated with dermatology utilization 
The majority of the study cohort had CD (63.1%). Increased disease duration was 
associated with dermatologic care (Table 14). There were no differences in disease location, 
behavior, extent, or perianal disease between the two groups. Those with dermatology care were 
more likely to ever have elevated serum markers of inflammation including ESR and CRP 
(Table 14). Medications exposures associated with dermatologic care included biologics, 
methotrexate, systemic and topical steroids (all p<0.001), but not thiopurines. Quality of life 
scores and active disease status was not different between groups. However, a larger proportion 
of patients with dermatology use was hospitalized or used the ER over the study period (all 
p<0.01). Dermatology use was associated with an increased number of digestive telephone 
encounters and digestive clinic visits (p<0.001) (Table 14). 
After adjusting for covariates, factors that remained significantly associated with 
dermatology utilization were employment status, family history of skin cancer, longer disease 
duration, systemic steroids, any emergency room use, and increasing number of IBD related 
clinic visits (Table 15). Elevated CRP was negatively associated with dermatology use (Table 
15). We did not adjust for topical steroid use, as this is likely an outcome of visiting 
dermatology. 
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Table 15. Multivariate logistic regression of factors associated with dermatology utilization 
  Adjusted Odds Ratio 95% CI p-value 
Dermatology utilization*     
Female  1.01 [0.74 – 1.4] 0.964 
Employment status    0.012† 
Full time or self employed  Reference   
Not employed  0.85 [0.55 – 1.30] 0.451 
Part time  1.24 [0.48 – 3.21] 0.656 
Full or part time student  1.84 [1.09 – 3.11] 0.023 
Retired  0.80 [0.45 – 1.43] 0.395 
Unknown  0.47 [0.25 – 0.86] 0.015 
Family history of skin cancer  13.22 [7.31 – 23.9] <0.001 
Years of disease  1.02 [1.01 – 1.04] 0.003 
Abnormal CRP  0.62 [0.42 – 0.89] 0.011 
Abnormal ESR  1.33 [0.93 – 1.91] 0.123 
Exposure to biologics  1.18 [0.85 – 1.63] 0.317 
Exposure to methotrexate  1.28 [0.84 – 1.95] 0.249 
Exposure to systemic steroids  1.68 [1.19 – 2.37] 0.003 
Emergency room visit  2.31 [1.60 – 3.33] <0.001 
Hospitalization   0.71 [0.49 – 1.04] 0.077 
Total digestive clinic visits  1.06 [1.02 – 1.09] <0.001 
Total digestive telephone 
encounters 
 1.00 [1.00 – 1.01] 0.487 
 
4.3.6 Skin cancer screening 
A total of 55 (2.59%) IBD patients in the cohort had a dermatology visit for a total body 
skin exam at least once over the study period. Of those with a clinic visit at the digestive clinic, 
the proportion of patients undergoing skin cancer screening with dermatology ranged from 0.2 – 
2.1% of patients per year (Table 13). We also evaluated the percentage of IBD patients who 
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were recommended for preventive care screening by the CCFA and ACG (Figure 3). The CCFA 
cohort was larger and 0.8% of this group received a total body skin exam per year (Figure 3, 
Table 13). Of the ACG recommended patients, an average of 2.2% received skin cancer 
screening per year (Figure 3, Table 13). Given the limitations of the methodology of identifying 
total body skin exams, these may be underestimated by approximately 20%, which would 
suggest 1.1% of the IBD patients, 0.9% of the CCFA and 2.7% of the ACG groups likely 
underwent skin cancer screening by a dermatologist.  
We determined the number of patients with primary care visits each year in an attempt to 
account for abbreviated skin cancer screenings and found an average of 8.7% (95% CI: 8.0% - 
9.3%) of IBD patients visited a primary care office within the health system each year.  
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Figure 3. Proportion of patients with inflammatory bowel disease who visited dermatology 
(A) Total number of unique patients in each category (IBD clinic visit, CCFA guidelines, ACG 
guidelines, per year. (B – D) The proportion of patients with a dermatologic clinic or procedural visit 
within the calendar year, and the proportion of patients with a total body skin exam for skin cancer 
screening per year. 
ACG, American College of Gastroenterology; CCFA, Crohn’s and Colitis Foundation; IBD, inflammatory bowel 
disease; TBSE, total body skin examination 
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4.3.7 Skin cancer diagnoses 
Using pathology reports and dermatology clinic and procedure visit diagnoses, there were 
a total of 12 (0.56%) patients with cutaneous squamous cell carcinoma, 15 patients (0.71%) with 
basal cell carcinoma, and 5 patients (0.24%) with melanoma diagnosed between the years 2010 – 
2016. Overall, in our IBD cohort, the incidence of NMSC was 35.4 /10,000 [95%CI: 23.3 – 
51.5]. There were also, five patients with melanoma, with an incidence of 6.56 / 10,000 [95%CI: 
2.1 – 15.3]. Of the five IBD patients diagnosed, the stages of melanoma ranged from in-situ 
melanoma (n=1, 20%) to stage IV metastatic melanoma (n=2, 40%). The remaining two 
intermediate melanomas were stage I with Breslow depths of 0.25mm and 0.45mm. The patients 
diagnosed with stage IV metastatic melanoma were ages 63 and 81, and both passed away within 
the study period.  
4.4 DISCUSSION 
In this observational study we used a multiyear, prospectively collected dataset to 
evaluate the dermatologic care patterns of IBD patients. We discovered 21.3% of patients saw 
dermatology and only 2.6% of our study population was screened for skin cancer at least once 
over the study period. Approximately, 8% of IBD patients seek care from a dermatologist or 
dermatology clinic each year. While there is a wealth of literature dedicated to the dermatologic 
complications of IBD including increased non-melanoma and melanoma skin cancer risk,26–28,101 
few IBD patients in this study sought dermatologic consultation and fewer obtained skin cancer 
screening.  
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These findings are similar to other studies examining preventive care habits in IBD 
patients, including cervical cancer screening, which found preventive care fell below 
recommended guidelines.105,106 In a recent study, only 11% of IBD patients within the Veterans 
Health Administration dataset obtained dermatologic care over a 10-year study period.105 This is 
less than our study showing 21.3% of patients over 7 years visited dermatology. However, there 
are likely inherent differences between our study population and veterans, including gender, 
which may impact risk for skin cancers and overall dermatology utilization.   
We also compared our findings of low dermatology utilization to those in the solid organ 
transplant population who also have prolonged exposure to immunosuppressive 
medications.107,108 A questionnaire study estimated around 14% of solid organ transplant patients 
have regular dermatologic skin care, which is higher than our observed 8% among IBD 
patients.109 This same study suggested over half of transplant patients would be interested in skin 
cancer screening by a dermatologist.109 While there are models incorporating total body skin 
exams for transplant patients, the adoption of formal skin surveillance varies among transplant 
clinics.110,111 Interestingly, a qualitative study suggested that kidney transplant recipients were 
aware of their increased risk of skin malignancy, but expressed uncertainty regarding cancer 
screening recommendations, and expected guidance on screening from a health 
professional.112,113 Additionally, patients and were most concerned about acute healthcare 
problems concerning their transplant.112 These thoughts and attitudes may apply to the IBD 
patient population, but the extent to which these themes apply is unknown.9,114  
We found that exposure to biologics was associated with dermatology use. A recent study 
suggested nearly a third of IBD patients initiating anti-TNF agents experience skin lesions, 
which provides rationale to why biologic use is associated with dermatologic care on univariable 
 68 
analysis.96 Biologics may also be used to treat certain dermatologic manifestations. Interestingly, 
exposure to thiopurines was not associated with dermatologic use. Thiopurines are frequently 
associated with increased risk of skin malignancy.27,100,101 This finding may suggest while 
evidence and guidelines are available, the translation and implementation of these data into the 
practice of increased dermatologic care and skin cancer surveillance is lacking.  
After adjusting for significant factors, family history of skin cancer remained strongly 
associated with dermatology use, which may imply a heightened awareness to the risk of skin 
cancer in these patients. However, this likely represents an information bias as the intake process 
of a dermatologic visit includes standard questions about family history of skin cancer, and this 
information may not be routinely obtained in primary care or gastroenterology visits. Systemic 
steroid use also remained significant, which may reflect side effects of steroid use, underlying 
IBD severity, or treatment of dermatologic conditions that require immunosuppression. 
Interestingly, increasing numbers of digestive visits and increasing disease duration of IBD are 
associated with dermatology use. These variables indirectly represent face time with a 
gastroenterology practitioner and suggest that preventive care guidelines may be discussed more 
frequently as time with gastroenterology providers increases. 
The low proportion of patients obtaining dermatologic care potentially contributed to the 
lower incidence of NMSC in our patient population which was significantly lower than 
published NMSC incidence rates in IBD of 73.3 per 10,000.27 There may be a subset of IBD 
patients with NMSC that is currently undiagnosed. Interestingly, our IBD cohort had similar 
incidence of melanoma compared to recent population based estimates of melanoma in IBD (2.0 
to 6.1/10,000).26,28 However, these were surprisingly advanced melanomas with two patients 
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diagnosed with metastatic disease. Improvement of access to screening and dermatology can 
help facilitate early detection of thinner melanomas.115 
Limitations of this study include that it was based at a single tertiary care center and may 
not be representative of other populations or other geographic regions, given that sun exposure 
and skin cancer awareness may vary with climate. The IBD population may also have more 
severe disease at baseline given the referral center. This study was also completely dependent on 
electronic coding and ICD codes which have many limitations and likely oversimplify the patient 
encounter. This study spanned seven years, but we do not capture any preventive care occurring 
prior to 2010 and the utilization of the electronic medical record. 
This study does not include dermatologic care obtained through local private practice 
clinics not linked to the UPMC outpatient medical record which limits the true estimation of 
dermatologic care obtained. However, our dataset captures all outpatient care in any UPMC 
affiliated hospital or clinic (comprising over 20 hospitals and 500 clinics), and UPMC 
dermatology provides a large proportion of care for the area. We also do not capture total body 
skin exams that occur in the primary care office using this study design. We evaluated the 
number of patients with primary care visits within the health system each year in an attempt to 
account for primary care screenings and found an <10% of IBD patients visited a UPMC 
affiliated primary care office each year. While this is likely an underestimation, given we do not 
capture private practitioners, literature suggests only 15-31% of PCP visits include a skin 
examination.116,117 This study required consented enrollment in a prospective IBD research 
registry, which is subject to participant bias, as those who volunteer for the registry may not be 
representative of all IBD patients. Despite these limitations, even if the potentially missing IBD 
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patients obtaining of dermatology care were included, still suggest only a minority of the 
recommended patients are obtaining skin cancer screening. 
A notable strength of this study is the use of a longitudinal multiyear dataset to evaluate 
care patterns over time. This approach overcomes biases associated with a pure cross-sectional 
analysis and provides an annual internal validation of our findings. As such, we observed that the 
trends of dermatologic care utilization and skin cancer screening were relatively stable over time. 
This analysis captures real world care patterns. The IBD registry is a not an interventional study 
and thus is not subject to changes in patient or provider behavior due to being observed.  
In conclusion, this study highlights the low skin cancer surveillance in a tertiary referral 
IBD population, and suggests the need to understand patient and provider awareness and 
attitudes toward guidelines for screening and dermatology involvement and in comprehensive 
IBD care. Despite the high prevalence of skin complications, and the increased risk of skin 
cancers, IBD patients rarely seek dermatologic care and skin cancer screening.   
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5.0  COST-EFFECTIVENESS OF MELANOMA SCREENING IN INFLAMMATORY 
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5.1 INTRODUCTION 
Inflammatory bowel disease (IBD) is a collection of immune mediated disorders of the 
gastrointestinal tract including Crohn’s disease and ulcerative colitis. It is estimated that 40% of 
patients will experience extraintestinal manifestations of IBD, with skin complications being one 
of the most common.24 IBD skin complications include an increased risk of melanoma and non-
melanoma skin cancers.26–28 Overall, IBD is associated with a 33% increase in melanoma risk.26 
While the etiology of the increased susceptibility is not fully known, evidence suggests 
medication exposures and disease related inflammation may contribute to the elevated risk of 
skin malignancy.31  
Currently, there are no clear recommendations for melanoma screening in the general 
United States (US) population. In 2009 and again in 2016, the US Preventive Services Task 
Force report did not recommend routine skin cancer screening, citing lack of evidence of 
anticipated harms and benefits with screening.118,119 Since the initial 2009 recommendations, 
some evidence in favor of skin cancer screening and associated reduced mortality has evolved. 
Research studies suggest that melanoma awareness and screening are associated with increased 
melanoma diagnoses, thinner melanomas, and a reduction in melanoma related mortality.120–122 
However, these studies were primarily performed in large population based cohorts, and do not 
provide specific information about high-risk populations, such as IBD. IBD specific guidelines 
encourage patient awareness, self skin exams, and referral of patients for a skin examination by a 
physician.98 The American College of Gastroenterology (ACG) preventive medicine guidelines 
for IBD patients suggest an annual melanoma screening skin exam, independent of biologic 
therapy.98 It is also recommended that patients on immunomodulators (6-mercaptopurine or 
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azathioprine) also obtain a skin cancer-screening exam due to an increased risk of non-melanoma 
skin cancers.98  
A handful of studies over the last two decades have evaluated the cost-effectiveness of 
national melanoma screening programs.33 Overall, these studies suggest that annual population-
wide screening is cost prohibitive and may result in unnecessary morbidity from screening in low 
risk persons. However, the studies generally agree that screening patients at higher risk of 
melanoma (i.e. siblings of persons with melanoma) are cost-effective strategies.33 Despite the 
published studies evaluating population based screening, it is uncertain how this translates to 
IBD patients with increased risk of skin cancers.  
Our primary aims were to determine the costs and effectiveness of the guideline 
recommended annual melanoma screening in the IBD population, and two alternative strategies 
of screening every other year and once at age 50. We also sought to determine the variables that 
most influence the cost-effectiveness of screening and their respective thresholds to optimize a 
cost-effective pragmatic approach to melanoma screening for IBD patients. 
5.2 MATERIALS AND METHODS 
5.2.1 Model Structure and Perspective 
Using TreeAge Healthcare Pro 2015 software (TreeAge Software Inc., Williamstown, 
MA), we created a Markov state-transition model to evaluate the cost-effectiveness of skin 
cancer screening by a dermatologist compared to routine background screening. Screening for 
melanoma occurs from ages 40 - 80. We used a six-month cycle length over a lifetime horizon. 
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All costs were measured in US Dollars and adjusted to the equivalent 2016 dollar using the 
Consumer Price Index inflation calculator.123 Effectiveness was measured in quality adjusted life 
years (QALYs). Future costs and QALYs were discounted at 3% per year. Our primary 
measured outcomes of the model were costs and effectiveness. Our predetermined willingness-
to-pay (WTP) threshold was set at $100,000/QALY, based on contemporary US benchmarks.124 
 
 
Figure 4. Markov state transition model 
Health states included in model with shaded health states indicating the presence of melanoma, 
or history of melanoma. 
5.2.2 Model Cohort 
Our hypothetical cohort included adult IBD patients of average disease severity. IBD 
patients remained melanoma free and acquired melanoma based on published incidence rates that 
reflected their increased melanoma risk due to IBD.26 Once patients developed melanoma, they 
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transitioned to an undiagnosed melanoma state (Figure 4). Patients with undiagnosed melanoma 
subsequently either had it detected by a physician or remained in the undiagnosed melanoma 
state (Figure 4).  Melanoma detection rates for dermatologists and PCPs were obtained from 
published literature (Table 16). Once diagnosed, patients were classified as having local (Stage 1 
or 2) or regional/distant (Stage 3 or 4) melanoma.125 After the melanoma diagnosis, patients 
became melanoma survivors or died. Melanoma survivors entered a melanoma surveillance 
program of total body skin exams every six months, and had an increased likelihood of 
developing a second primary melanoma, which was influenced by age.126  
Melanoma incidence and survival statistics were obtained from the Surveillance, 
Epidemiology, and End Results (SEER) database.127 Patients with melanoma, regardless of 
diagnostic status, had higher mortality according to disease stage than did patients who were 
melanoma free. Age and gender specific US life tables determined survival estimates in the 
melanoma-free population and background mortality.128 
5.2.3 Model Assumptions 
In order to model melanoma screening in IBD patients, we made a number of 
assumptions. We assumed all IBD patients had the same average relative risk of melanoma. We 
did not model differences in IBD disease severity or exposure to IBD therapies. There is primary 
literature suggesting anti-tumor necrosis factor (anti-TNF) exposure increases melanoma risk in 
IBD and in other populations routinely exposed to biologics.28,29 However, our base case relative 
risk of melanoma in the IBD population did not incorporate any additional risk of exposure to 
biologic therapy, as the recent meta-analysis from which it was derived did not provide definitive 
evidence regarding therapeutic influences on melanoma risk in IBD.26 Given the ongoing 
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uncertainty of this parameter, relative risk of melanoma was varied over plausible ranges in 
sensitivity analyses. We assumed adherence to annual skin cancer screening would be similar to 
overall adherence to IBD-related appointments and medical therapy, which was derived from the 
literature (Table 16). 
Localized melanomas are defined as one category within the SEER database. We 
assumed that approximately 75% of diagnosed melanomas confined locally would be stage 1 
melanomas (tumor thickness <1.0mm and/or between 1.01-2.0mm without ulceration), and the 
other 25% stage 2 melanomas (tumor thickness between 1.01-2.00mm with ulceration, or any 
tumor >2.01mm without nodal involvement regardless of thickness).125 We assumed that 10% of 
all undetected local melanomas would transition to regional/distant melanoma in the following 
year based on expert opinion and consistency with previous melanoma screening cost-
effectiveness analyses.34 Additionally, while melanoma screening programs are likely to detect 
NMSCs, including basal cell carcinoma and squamous cell carcinoma, we did not include this 
detection in our model as this analysis has been shown to be cost-effective in Crohn’s disease 
patients previously.129 
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Table 16. Model probabilities, costs, and utilities 
  Monte-Carlo 
Distribution 
  
 Base Case Low 
Value 
High 
Value 
Distribution Reference 
Probabilities (%)      
Background skin cancer 
screening 
10 0.9 24.5 Beta 102,103,130 
Annual screening adherence  82.6 63.3 95.4 Beta 131,132 
Screening adherence with 
history of melanoma 
96.0 90.7 99.4 Beta 133 
Dermatologist sensitivity 89.0 66.1 99.0 Beta 134 
PCP sensitivity 80.0 67.9 91.6 Beta 134 
Melanoma: Stage I or II  
(Local) 
84.0 68.8 94.4 Beta 127 
Local melanoma, 
Dermatologist screened 
91.7 75.9 98.1 Beta 135 
Local melanoma, PCP 
screened 
83.4 72.3 91.3 Beta 135 
Melanoma: Stage III 8.9 7.3 10.9 Beta 127 
Melanoma: Stage IV 3.8 2.2 5.7 Beta 127 
Progression: local to distant 
melanoma 
10.0 3.4 20.5 Beta Expert 
opinion34 
      
Costs ($)      
Skin cancer screening exam 108.85 37.15 264.97 Gamma 136 
Melanoma diagnosis/biopsy 104.55 41.75 200.90 Gamma 136 
Melanoma: Stage I or II 
(Local) 
4,027.20 1,267.06 9,926.75 Gamma 137 
Melanoma: Stage III 13,646.81 7,845.79 20,753.99 Gamma 137 
Melanoma: Stage IV 27,237.19 9,108.28 20,753.99 Gamma 137 
      
Utilities      
Inflammatory bowel disease 0.800 0.670 0.899 Beta 138 
Active melanoma diagnosis      
Melanoma: Stage I 0.93 0.791 0.992 Beta 139 
Melanoma: Stage II 0.92 0.681 0.998 Beta 139 
Melanoma: Stage III 0.72 0.533 0.853 Beta 139 
Melanoma: Stage IV 0.58 0.418 0.736 Beta 139 
History of melanoma      
Melanoma: Stage III 0.94 0.812 0.996 Beta 139 
Melanoma: Stage IV 0.50 0.319 0.697 Beta 139 
      
Other parameters      
Relative risk of melanoma in 
IBD 
1.33 1.0 2.95 Log normal 26 
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NNB – Dermatologist 17.4 9.86 26.3 Gamma 140 
NNB – PCP 32.8 24.15 42.25 Gamma 140 
PCP – primary care physician; IBD – inflammatory bowel disease; NNB – number needed to 
biopsy to diagnosis one melanoma 
 
5.2.4 Costs and Effectiveness 
Cost estimates associated with melanoma screening and treatment were obtained from 
published literature and US databases, as were utilities for IBD and stages of melanoma (Table 
1). Medicare physician fee schedules were used to estimate the costs associated with a screening 
visit and skin biopsy.136 Effectiveness was measured in QALYs. QALYs of average IBD and 
melanoma health states were derived from published literature (Table 16), and were adjusted by 
age.141 Age based utility from 40-54 years old was 0.92, from 55-64 years was 0.88, and for 65+ 
years was 0.84.141 
5.2.5 Screening Strategies 
The base case skin cancer screening strategy included an annual total body skin exam by 
a dermatologist. This screening program began at age 40 years and continued until death or 80 
years of age. This was compared to background rates of skin cancer screening by primary care 
practitioners which were estimated through published literature.102,103,130 Background screening 
was not dependent on age and continued until death in both strategies. We also evaluated 
alternative screening strategies to reduce the overall screening intensity on IBD patients 
including screening every other year and screening once at age 50. All other model parameters 
remained the same during the evaluation of the alternative frequency screening strategies.  
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5.2.6 Cost-Effectiveness Analysis  
A series of one-way sensitivity analyses were performed to determine the variables that 
most influence the incremental cost effectiveness ratio (ICER), defined as the change in cost 
over the change in effectiveness. Variables were evaluated over plausible ranges, and guided by 
available published literature. We used deterministic sensitivity analyses to define parameter 
thresholds at WTP levels of $100,00/QALY and $150,00/QALY. We employed probabilistic 
sensitivity analysis simultaneously sampling parameter distributions over 10,000 trials, to 
determine the percent of model iterations favoring screening at predetermined WTP levels. We 
used beta distributions for probabilities and utility values, and gamma distributions for cost 
parameters and number needed to biopsy variables (Table 16).142 Relative risk for melanoma 
was modeled using a log-normal distribution.142  
5.3 RESULTS 
5.3.1 Base-Case Analysis & Screening Strategies 
In the IBD population, annual melanoma screening by a dermatologist cost $1961 per 
person compared to background screening which was $81 per person (Table 17). Annual 
screening was more effective, gaining an additional 9.2 QALYs per 1000 persons. The resulting 
ICER for the base case analysis was $203,400/QALY (Table 17).  We also evaluated screening 
every other year from ages 40 to 80 years old. In this scenario, screening costs an average of 
$999 per person, while background screening costs remained the same at $81 per person. 
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Incremental effectiveness decreased to 6.4 QALYs per 1000 persons resulting in an ICER of 
$143,959/QALY. Finally, screening for melanoma once at age 50 resulted in lower screening 
costs, lower incremental effectiveness of screening of only 0.4 QALYs per 1000 persons, and a 
lower ICER as compared to the base case (Table 17).  However, the ICER of the strategy to 
screen once at age 50 was $153,518/QALY, and was dominated by the strategy of screening 
every other year (Table 17).  
 
Table 17. Cost effectiveness analysis results 
 Cost Incremental Cost Effectiveness 
Incremental 
Effectiveness 
Incremental cost-
effectiveness ratio 
No screening/ background $81 - 16.5924 - - 
Base case: annual 
screening $1961 $1880 16.6017 0.0092 $203,400 /QALY 
Screening every other year $999 $918 16.5988 0.0064 $143,959 /QALY 
Screening once at age 50 $148 $66 16.5928 0.0004 $153,518 /QALY 
 
 
All three evaluated scenarios did not meet the WTP threshold of $100,000/QALY gained. 
Therefore, melanoma screening is not strictly cost-effective or the preferred strategy as 
compared to background levels of skin cancer screening. However, given the three tested 
strategies, the most cost-effective approach is screening every other year with an ICER of 
$143,959/QALY, which is lower than screening annually and screening once at age 50.  
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Table 18. One-way sensitivity analyses 
   Resulting ICER Willingness to pay threshold 
 Base case Range Low value High value $100,000 / QALY 
$150,000 / 
QALY 
Base case: annual 
screening     
  
Progression percentage 10% 2% – 15% $382,815 $181,799 n/a* n/a* 
Relative risk of 
melanoma in IBD 1.33 1.0 – 4.0 $268,394 $72,356 2.81 1.83 
Cost of melanoma 
screening $108.85 $25 - $200 $46.383 $374,088 $53.63 $80.33 
Alternative strategy: 
screening every other year     
  
Progression percentage 10% 2% – 15% $231,734 $142,307 n/a 8.15% 
Relative risk of 
melanoma in IBD 1.33 1.0 – 4.0 $189,560 $52,255 1.95 1.27 
Cost of melanoma 
screening $108.85 $25 - $200 $33,023 $264,554 $75.62 $113.42 
ICER – incremental cost effectiveness ratio; IBD – inflammatory bowel disease; QALY – 
quality adjusted life year 
* Value outside of plausible range given specified willingness to pay threshold. 
5.3.2 One-Way Sensitivity Analyses 
5.3.2.1 Percent progression from local to regional melanoma 
The percent of patients progressing from local to regional disease over time is unknown 
and our value was based on previously published models for consistency. Given this uncertainty, 
we performed one-way sensitivity analysis on this parameter from 2% progression to 15% 
progression in the base case annual melanoma screening scenario. Despite varying the parameter 
from 2-15%, there was no value that satisfied WTP cutoffs of $100,000 or $150,000/QALY.  As 
the progression percentage increased, the ICER decreased from $382,815/QALY at 2% 
progression to $181,799/QALY at the highest estimate of 15% progression (Table 18).     
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When we repeated this one-way sensitivity analysis in the favored strategy of screening 
every other year, we obtained similar results. As the progression percentage increased, the ICER 
decreased from $231,734/QALY at 2% progression to $142,307/QALY at the highest estimate of 
15% progression (Table 18).  
At low progression percentages, screening every other year is the clearly preferred 
strategy (>$150,00/QALY difference) as compared to screening annually. While at higher 
progression percentages the differential in the ICERs of the two strategies of screening annually 
or every other year is smaller (approximately $40,000) (Table 18). 
5.3.2.2 Relative risk of melanoma in IBD 
There is relative uncertainty in the increased melanoma risk in IBD patients. We used a 
conservative estimate of a relative risk (1.33) derived from a meta-analysis.26 In our one-way 
sensitivity analyses we evaluated relative risks between 1.0 and 4.0. In the base case strategy of 
screening every year, the ICER is less than $100,00/QALY if the relative risk of melanoma in 
IBD patients is greater than 2.81 (Table 18). The ICER is less than $150,000/QALY if the 
relative risk of melanoma in IBD is less than 1.83 (Table 18). 
We performed the same sensitivity analysis of the relative risk of melanoma in the 
favored strategy of screening every other year. Results of one-way threshold analysis for this 
strategy were similar. When screening every other year, the ICER remains less than 
$100,000/QALY as long as the relative risk of melanoma in IBD patients is greater than 1.95 
(Table 18). The ICER remains less than $150,000/QALY as long as the relative risk of 
melanoma in IBD is less than 1.27, which is slightly less than the base case parameter (Table 
18).  
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5.3.2.3 Cost of melanoma screening by a dermatologist 
Melanoma screening cost significantly influenced results. The base case cost of screening 
was $108.85.136 We varied this cost in one-way sensitivity analysis from $25 to $200 in the 
annual screening strategy. To maintain an ICER under a WTP threshold of $100,000/QALY, 
screening cost must remain less than $53.63 per exam (Table 18).  When we repeated the one-
way sensitivity analysis in the more favored strategy of screening every other year, screening 
costs needed to remain less than under $75.62 per screen to result in an ICER less than 
$100,000/QALY gained (Table 18). 
 
 
Figure 5. Two-way sensitivity analysis 
Two-way sensitivity analysis of the progression percentage of melanoma (y-axis), and the 
relative risk of melanoma in inflammatory bowel disease patients (x-axis). Separation plane is a 
willingness to pay threshold of $100,000/QALY. Preferred strategy (screening every other year 
or no screening) is labeled in each respective area. 
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5.3.3 Two-way sensitivity analysis 
While not strictly cost effective compared to our WTP threshold, screening every other 
year was the preferred strategy as compared to the base case and guideline recommendations of 
screening annually. One-way sensitivity analyses demonstrated that the relative risk of 
melanoma and the percent progression from local to regional disease have an important influence 
on the ICER (Table 18). We performed two-way sensitivity analyses on these parameters, 
varying them simultaneously, as they are both uncertain characteristics of melanoma, which may 
be different in the setting of IBD. Two-way sensitivity analysis was performed for the screening 
strategy of every other year (Figure 5). Screening every other year is favored at higher relative 
risks and increased probabilities of melanoma progression, as indicated in Figure 5.  
5.3.4 Probabilistic Sensitivity Analyses 
We evaluated the screening every other year strategy using probabilistic sensitivity 
analysis over 10,000 trials. Screening every other year was cost effective in 17.4% of model 
iterations at a WTP threshold of $100,000/QALY. At a WTP threshold of $150,000/QALY, 
screening every other year was cost effective in 44.8% of iterations (Figure 6).  
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Figure 6. Probabilistic sensitivity analysis 
Cost-effectiveness acceptability curves show the likelihood that melanoma screening (black 
square) and no screening (open circle) are considered cost-effective over a range of willingness-
to-pay thresholds when parameters are simultaneously varied over their distributions. 
5.4 DISCUSSION 
Screening for melanoma in IBD patients was effective but expensive. With a WTP 
threshold of $100,000/QALY in place, screening for melanoma in the IBD population was not 
cost-effective. Compared to background rates of skin exams by PCPs, dermatology based 
screening for melanoma in IBD patients was more effective, but substantially more expensive. 
Of the three strategies examined, screening for melanoma every other year was the preferred 
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strategy. Screening every other year was more cost effective, under the $100,000/QALY 
threshold, than screening once at age 50 or screening annually.  
Our one-way sensitivity analyses suggest that the cost-effectiveness of melanoma 
screening depends on the percent of melanomas that progress from local to regional disease. This 
finding is consistent with previous models of melanoma screening in the general population.34 
Interestingly, this variable is difficult to define and currently unknown. Our chosen estimate was 
based on previous models and was not IBD specific. IBD specific estimates of this parameter 
may influence the overall cost-effectiveness of melanoma screening programs. 
The relative risk of melanoma was also varied in sensitivity analyses. Of the papers 
included in the systematic review from which the base case relative risk of 1.33 was derived, the 
relative risk of melanoma ranged from 0.70 to 5.41.26 However, the majority of relative risk 
estimates of melanoma in IBD were between 1.00 and 2.00.26 Additionally, while not statistically 
different between groups, Crohn’s disease patients had an increased incidence of melanoma 
compared to ulcerative colitis, with a relative risk of 1.51 and 1.23, respectively.26 This suggests 
initially targeting screening to Crohn’s disease patients could be one way to stratify patients who 
are higher risk.  
There are also studies suggesting medication exposures can increase risk of melanoma in 
immunosuppressed populations including IBD.28,29,99 Long, et al reported an increase in 
melanoma in IBD over time, which paralleled the increase in biologic use in years 1997 – 
2009.28 Additionally, subgroup analyses suggested patients with long-term duration of anti-TNF 
biologics demonstrated increased odds of melanoma compared to those with short-term use.28 
While these findings require validation, duration of immunosuppression and exposure to 
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biologics could be used to target dermatologic screening to IBD patients at highest risk of 
melanoma making screening more cost-effective.  
In this study, our WTP threshold was set at $100,000/ QALY gained.  However, the 
selection of WTP thresholds remain somewhat arbitrary for programs evaluated in the United 
States. Therefore, our results should be taken in context given WTP thresholds are often 
predetermined cutoffs and do not accurately translate to programmatic decisions or justify 
implementation. It is often recommended to evaluate programs upon a continuum of WTP 
thresholds from $50,000 to $200,000/ QALY.124 The preferred strategy of screening every other 
year has an ICER of $143,959/ QALY, which fits comfortably in the suggested range of 
evaluation. However, screening every year for melanoma is at the high end of the range of WTP 
thresholds, slightly above $200,000/ QALY. While our current preventive care guidelines in IBD 
recommend annual screening, screening every other year may present an opportunity to modify 
of our approach of preventive skin cancer screenings by dermatologists. Other potential 
modifications may include, but are not limited to, partnering with dermatology in new holistic 
care models including IBD medical homes, incorporating teledermatology to increase patient 
access to dermatologic care, as well as increasing the focus on primary prevention and education 
about skin cancer to improve early self detection in IBD patients.143,144  
Our analysis is limited as data are derived from multiple sources, each associated with 
their own inherent biases. Additionally, there are unknown parameters and remaining uncertainty 
in parameters relating specifically to the risk and behavior of melanoma in IBD patients. We also 
did not include NMSC in our model. IBD patients are at an increased risk of NMSC and it is 
more prevalent than melanoma, however, it is rarely fatal.27,28 NMSC is similarly discovered 
through total body skin exams, and the detection of NMSC would add costs as well as benefits. 
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A recent paper by Okafor, et al, suggests screening for NMSC in patients with Crohn’s disease is 
cost effective. They found screening all Crohn’s disease patients annually was the most cost-
effective strategy, with every other year screening as the second best strategy.129 The addition of 
NMSC screening may improve the ICER of this study, however we sought to specifically model 
melanoma, and the additional costs and benefits of NMSC detection is outside the scope of this 
analysis. 
While current preventive care guidelines exist to promote annual skin exams in IBD, it is 
uncertain how frequently IBD patients currently obtain skin cancer screening. Our estimates of 
background screening were derived from the general population, which is likely an 
underestimation as IBD patients generally have increased healthcare contact. However, this data 
on physician and patient adherence to skin cancer screening guidelines in the IBD population is 
unknown. Proper estimates of background screening in IBD will further clarify the potential 
benefits of a melanoma screening program and strengthen our analysis. 
In summary, compared to background primary care exams, screening annually for 
melanoma in IBD patients was more effective, but more expensive. Screening for melanoma 
every other year by a dermatologist was the preferred strategy. Future research evaluating the 
risk and behavior of melanoma in IBD, including determining therapies most associated with 
increased risk of melanoma, is needed to clearly define the costs and benefits of melanoma 
screening. While research is ongoing, primary prevention of skin cancers through counseling on 
sun protection remains of utmost importance among IBD patients. Presently, targeting IBD 
patients at the highest risk of developing melanoma, such as those with certain medication 
exposures or a family history of skin cancer, for dermatologic exams will assist in designing the 
most cost-effective approach to melanoma screening in IBD.  
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6.0  CONCLUSIONS 
In the first chapter of the dissertation, we described the methodology of generating large 
observational datasets from the electronic medical record, and how these can be used to discover 
and refine patient phenotypes in IBD. We outlined challenges to abstracting real-world data, and 
how these have been overcome with a systematic and efficient approach in the IBD research 
registry. The IBD research registry served as a critical data source for the first two research 
questions addressed in this dissertation and many other projects outside the scope of this work.  
In the second chapter we generated a propensity matched cohort of IBD patients through 
which we could define the long-term impact of Clostridium difficile infection. Propensity 
matching allowed us to account for the measurable differences between IBD patients who are 
likely to get infection and those who are not. We matched based on variables that are associated 
with an increased risk of infection, including antibiotic and healthcare exposure. This 
methodology overcomes many of the difficulties of using a random sample as a comparison 
group. The resulting matched groups were similar in all measurable outcomes in the year prior to 
infection. We found that Clostridium difficile infection was significantly associated with more 
steroid and antibiotic exposure, elevated inflammatory markers, increased disease activity, worse 
quality of life, and increased healthcare utilization in the year of infection. During the year after 
infection, patients in the Clostridium difficile group continued to have increased exposure to 
Clostridium difficile targeted antibiotics and other systemic antibiotics, while having more clinic 
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visits, telephone encounters, and a five-fold increase in healthcare charges. These findings 
suggest that infection is associated with a measurable impact on healthcare utilization beyond 
one year. This includes both financial measures of healthcare utilization (healthcare charges), 
and non-cost generating measures (telephone calls), both of which are important to the total time 
and cost investment of taking care of patients.  
In the third dissertation chapter we evaluated the overall utilization of dermatology care 
among IBD patients in the research registry. We determined that 21% of IBD patients utilized 
dermatology from 2010-2016, and 2.6% of patients had a total body exam for skin cancer 
screening at least once over the same time frame. Each year, between 8% and 11% of patients 
recommended by gastroenterology preventive care guidelines visited dermatology for any 
indication. When we look at skin cancer screening specifically, only 0.8% to 2.5% of patients on 
average obtained a total body skin exam. These trends did not vary by different guideline 
recommendations, which stratify patients by medication exposures, nor did they vary over time. 
Overall, these findings suggest only a small proportion of IBD patients recommended for 
screening obtains dermatologic care for any indication. Additionally, the data imply that IBD 
patients are not screened according to medication exposures that introduce additional skin cancer 
risk. 
In the fourth project included in this dissertation, we used a Markov model to estimate 
intervention costs and effectiveness of melanoma screening in the IBD population. This model 
was generated in response to known guidelines that recommend screening for melanoma among 
IBD patients regardless of medication exposure. The data from the prior dissertation project 
suggest that patients are not obtaining screening, but we wanted to model the scenario that 
screening by a dermatologist was available to all IBD patients annually. This screen strategy was 
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compared to the background rates of skin cancer screening in the general population, performed 
by a primary care practitioner. Utilizing the cost effectiveness model we found screening for 
melanoma in IBD patients was more effective but also expensive. Among model variations, 
screening every other year was the most cost-effective strategy at $143,959 per quality adjusted 
life year gained. This strategy fits within cost effectiveness thresholds for the United States and 
may be an alternative approach to skin cancer screening by dermatologists in the IBD 
population. 
In conclusion, the included studies reveal the methodology of research data derived from 
the electronic medical record, the long-term impact of infection among IBD patients, the 
underutilization of dermatologic preventive care, and provide a cost effectiveness model to 
inform the development of skin cancer screening programs in IBD.  
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7.0  FUTURE DIRECTIONS 
Despite the work presented here many questions remain and deserve further 
investigation. Importantly, what can we do to reduce the impact of Clostridium difficile infection 
among IBD patients? There are new therapies available and in development that may be more 
effective at reducing recurrent infection.145 It is natural to wonder how this would modify the 
long-term impact of infection in IBD patients. There have also been cost effectiveness studies 
evaluating different treatment approaches in Clostridium difficile infection.146 However, these 
studies do not incorporate the cost figures we generated using a propensity matched cohort, nor 
are they specific to IBD. The financial impact that extends into the year after infection may be an 
important addition to such models. One could use the data presented here to evaluate the cost 
effectiveness of newer, more expensive therapeutics in the setting of IBD and Clostridium 
difficile infection, as compared to standard treatment regimens. 
In our second research project, we discovered only a small proportion of patients are 
seeking dermatologic care, which leads into the next question of…why? Through the 
multivariable analyses we determined there are a few factors associated with dermatologic use 
including family history of skin cancer and overall opportunities or face time for referral (clinic 
visits and emergency room utilization). However, using our methodology, the only aspects of 
care that we are able to objectively quantify are embedded in the electronic medical record. 
There are likely many reasons why patients do not seek or obtain skin cancer screening that are 
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difficult to measure without further investigation including patient and provider attitudes, 
knowledge, and barriers and facilitators of seeking care. These unanswered questions lend 
themselves to a qualitative study of both patients and providers that aims to understand each 
group’s thoughts, experiences and attitudes on the involvement of dermatology in all-
encompassing IBD care. 
After we understand the barriers and facilitators to dermatologic care in IBD we can best 
approach implementation of preventive screening. This pairs with the findings from our cost 
effectiveness study, which suggest a different screening interval from what is currently 
recommended may be the most cost effective approach to melanoma prevention in IBD patients. 
This study also raises a number of other ideas which may increase the efficiency of screening, 
including screening high-risk patients to reduce costs associated with a screening program. 
Additional studies to clarify how current and historical medication exposures and how the 
duration of exposures impact skin cancer risk in IBD patients are of the utmost importance. 
Developing a skin cancer risk stratification system among IBD patients is an important future 
endeavor which may increase the efficiency of skin cancer screening in IBD.   
Finally, as skin screening programs are implemented, it is critical to evaluate the 
implementation for continual quality improvement, acceptance, and to assess their performance. 
We lack an understanding of how skin cancer screening in IBD patients impacts clinical 
outcomes and quality of life. While this would be a large undertaking, the evidence would be 
extremely valuable to support current practices and guidelines.   
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APPENDIX A 
DERMATOLOGY VISIT CATAGORIES AND ANNUAL TRENDS OF VISIT 
INDICIATIONS 
This appendix contains two large tables referenced in Chapter 5. Low rates of 
dermatologic care and skin cancer screening among inflammatory bowel disease patients. 
 
Table 19. Categories of dermatology care and associated ICD9 and ICD10 codes 
Categories: Primary Diagnosis Codes   
   
Acneiform eruptions ICD 9 ICD 10 
Acne 706.1 L70.9 
Acne rosacea 695.3 L71.9 
Acne, unspecified acne type 706.1 L70.9 
Acne scarring 709.2 L73.0 
Acne vulgaris 706.1 L70.0 
Acneiform eruption 692.9 L30.9 
Cystic acne 706.1 L70.0 
Demodex acne 706.1 L70.8 
Nodulocystic acne 706.1 L70.8 
Other acne 706.1 L70.8 
Inflammatory papule 709.8 R23.8 
Dilated pore of Winer of back 706.1 L70.8 
Infestation by demodex folliculorum 133.8 B88.0 
Rosacea 695.3 L71.9 
   
Actinic keratoses and solar skin aging ICD 9 ICD 10 
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Actinic keratoses 702 L57.0 
Actinic keratosis 702 L57.0 
Actinic keratosis of left cheek 702 L57.0 
Actinic keratosis of scalp 702 L57.0 
AK (actinic keratosis) 702 L57.0 
Intrinsic aging of facial skin 701.8 R23.8 
Solar lentigo 709.09 L81.4 
Solar aging of skin 692.74  
Sun-damaged skin 692.79 L57.8 
Solar keratosis 702 L57.0, 
X32.XXXA 
   
Contact Dermatitis or Dermatitis ICD 9 ICD 10 
Allergic contact dermatitis 692.9 L23.9 
Allergic contact dermatitis due to metals 692.83 L23.0 
Allergic contact dermatitis due to other agents 692.89 L23.89 
Allergic contact dermatitis, unspecified trigger 692.9 L23.9 
Atopic dermatitis, unspecified type 691.8 L20.9 
Chondrodermatitis nodularis chronica helicis 380 H61.009 
Chondrodermatitis nodularis helicis 380 H61.009 
Contact dermatitis 692.9 L25.9 
Contact dermatitis and other eczema due to other 
chemical products 
692.4 L25.3 
Contact dermatitis and other eczema, due to unspecified 
cause 
692.9 L25.9 
Contact dermatitis due to chemicals 692.4 L25.3 
Contact dermatitis due to cosmetics, unspecified contact 
dermatitis type 
692.81 L25.0 
Dermatitis 692.9 L30.9 
Dermatitis, unspecified 692.9 L30.9 
Dermatitis due to cosmetics 692.81 L25.0 
Dermatitis due to metals 692.83 L23.0 
Chronic dermatitis of hands 692.9 L30.9 
Hand dermatitis 692.9 L30.9 
Irritant contact dermatitis 692.9 L24.9 
Irritant contact dermatitis due to chemical 692.4 L24.5 
Irritant contact dermatitis due to other agents 692.89 L24.89 
Irritant dermatitis 692.9 L24.9 
Dyshidrosis 705.81 L30.1 
Dyshidrotic hand dermatitis 705.81 L30.1 
Dyshidrotic eczema 705.81 L30.1 
Nummular eczema 692.9 L30.0 
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Eczema 692.9 L30.9 
Eczema, unspecified type 692.9 L30.9 
Eczematous dermatitis 692.9 L30.9 
Other eczema  L30.8 
Jacquet's dermatitis 691 L22 
Atopic dermatitis 691.8 L20.9 
Flexural atopic dermatitis 691.8 L20.89 
Papular atopic dermatitis 691.8 L20.89 
Perianal dermatitis 692.9 L30.9 
Stasis dermatitis 454.1 I83.10 
Stasis dermatitis of both legs 454.1 I83.11, I83.12 
Stoma dermatitis 692.9 L30.9 
Seborrhea 706.3 L21.9 
Seborrheic dermatitis 690.1 L21.9 
Perioral dermatitis 695.3 L71.0 
Periorificial dermatitis 695.3 L71.0 
Peristomal dermatitis 692.9 L30.9 
Other atopic dermatitis 691.8 L20.89 
Other atopic dermatitis and related conditions 691.8 L20.89 
Other dermatitis due to solar radiation 692.79 L57.8 
Superficial perivascular dermatitis 692.89 L30.8 
Palisaded neutrophilic and granulomatous dermatitis 692.9 L25.9 
   
Hair Loss or growth ICD 9 ICD 10 
Alopecia 704 L65.9 
Alopecia areata 704.01 L63.9 
Alopecia, scarring 704.09 L66.9 
Alopecia, unspecified 704 L65.9 
Hair loss 704 L65.9 
Lichen planopilaris 697 L66.1 
Lichen plano-pilaris 697 L66.1 
Male pattern alopecia 704.09 L64.9 
Scarring alopecia 704.09 L66.9 
Telogen effluvium 704.02 L65.0 
Hirsutism 704.1 L68.0 
   
Benign Neoplasm ICD 9 ICD 10 
Benign neoplasm groin skin 216.5 D23.5 
Benign neoplasm of other specified sites of skin 216.8 D23.9 
Benign neoplasm of skin 216.9 D23.9 
Benign neoplasm of skin of cheek 216.3 D23.39 
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Benign neoplasm of skin of lower limb, including hip 216.7 D23.70 
Benign neoplasm of skin of other and unspecified parts 
of face 
216.3 D23.30 
Benign neoplasm of skin of trunk, except scrotum 216.5 D23.5 
Benign neoplasm of skin of upper limb, including 
shoulder 
216.6 D23.60 
Benign neoplasm of skin, site unspecified 216.9 D23.9 
Benign neoplasm of skin of right lower extremity 216.7 D23.71 
Benign neoplasm of skin of upper limb, including 
shoulder, unspecified laterality 
216.6 D23.60 
Angioma 228 D18.00 
CNH (chondrodermatitis nodularis helicis)  380 H61.009 
Cherry angioma 448.1 I78.1 
Dermatofibroma 216.9 D23.9 
Inflamed skin tag 701.9, 686.9 L91.8 
Skin tag 701.9 L91.8 
Sebaceous hyperplasia 706.8 L73.8 
Fordyce spots 750.26 Q38.6 
Lentigines 709.09 L81.4 
Lentigo 709.09 L81.4 
DSAP (disseminated superficial actinic porokeratosis) 692.75 L56.5 
Lesion of nose 478.19 J34.89 
Porokeratosis 757.39 Q82.8 
   
Seborrheic keratoses ICD 9 ICD 10 
Seborrheic keratoses 702.19 L82.1 
Seborrheic keratoses, inflamed 702.11 L82.0 
Seborrheic keratosis 702.19 L82.1 
Seborrheic keratosis, inflamed 702.11 L82.0 
Inflamed seborrheic keratosis 702.11 L82.0 
Other seborrheic keratosis 702.19 L82.1 
Stucco keratosis 701.1 L85.1 
   
Nevus ICD 9 ICD 10 
Atypical nevus 216.9 D22.9 
Atypical nevus of back 216.5 D22.5 
Atypical nevus of upper back excluding scapular region 216.5 D22.5 
Dermal nevus of face 216.3 D23.30 
Dermal nevus of scalp 216.4 D22.4 
Dysplastic nevus 216.9 D23.9 
Dysplastic nevus of trunk 216.5 D22.5 
Dysplastic nevus of lower extremity, left 216.7 D23.72 
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Irritated nevus of cheek 216.3 D22.39 
Irritated nevus 216.9 D22.9 
Irritated nevus of neck 216.4 D22.4 
Intradermal melanocytic nevus 216.9 D22.9 
Melanocytic nevi of trunk 216.5 D22.5 
Melanocytic nevus 216.9 D22.9 
Multiple melanocytic nevi 216.9 D22.9 
Multiple melanocytic nevus 216.9 D22.9 
Multiple benign melanocytic nevi 216.9 D22.9 
Multiple benign nevi 216.9 D22.9 
Multiple nevi 216.9 D22.9 
Nevus 216.9 D22.9 
Nevus of multiple sites 216.9 D22.9 
Longitudinal melanonychia 703.8 L60.8 
   
Inflammatory bowel diseases, pyoderma, erythema 
nodosum, hidradenitis 
ICD 9 ICD 10 
Crohn disease(Notable Code) 555.9 K50.90 
Crohn's disease of both small and large intestine without 
complication(Notable Code) 
555.2 K50.80 
Crohn's disease(Notable Code) 555.9 K50.90 
Regional enteritis of small intestine with large 
intestine(Notable Code) 
555.2 K50.80 
Ulcerative colitis(Notable Code) 556.9 K51.90 
Pyoderma gangrenosa 686.01 L88 
Pyoderma gangrenosum 686.01 L88 
Pyostomatitis vegetans 528.09 K12.1 
Erythema nodosum 695.2 L52 
Parastomal pyoderma gangrenosum 686.01 L88 
Hydradenitis 705.83 L73.2 
Hidradenitis 705.83 L73.2 
Hidradenitis suppurativa 705.83 L73.2 
   
Cyst, carbuncle or furuncle ICD 9 ICD 10 
Cyst IMO0001  
Cyst of lip 528.5 K13.0 
Cyst of skin 706.2 L72.9 
EIC (epidermal inclusion cyst) 706.2 L72.0 
Epidermal inclusion cyst 706.2 L72.0 
Epidermal cyst 706.2 L72.0 
Subcutaneous nodule 782.2 R22.9 
Sebaceous cyst 706.2 L72.3 
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Carbuncle and furuncle of leg, except foot 680.6 L02.429 
Furuncle 680.9 L02.92 
Furunculosis 680.9 L02.92 
Pilar cyst 704.41 L72.11 
   
Infection (bacterial, fungal, viral) or infestation ICD 9 ICD 10 
Abscess 682.9 L02.91 
Abscess of buttock, left 682.5 L02.31 
Pustule 686.9 L08.9 
Dermatophytosis of foot 110.4 B35.3 
Dermatophytosis of groin and perianal area 110.3 B35.6 
Dermatophytosis of nail 110.1 B35.1 
Dermatophytosis of the body 110.5 B35.4 
Disseminated superficial actinic porokeratosis 692.75 L56.5 
Deep seated dermatophytosis 110.6 B35.8 
Tinea 110.9 B35.9 
Tinea manuum 110.2 B35.2 
Tinea corporis 110.5 B35.4 
Tinea versicolor 111 B36.0 
Pitted keratolysis 695.89 L98.8 
Pityriasis versicolor 111 B36.0 
Onychodystrophy 703.8 L60.3 
Onychomycosis 110.1 B35.1 
Intertrigo 695.89 L30.4 
Unspecified local infection of skin and subcutaneous 
tissue 
686.9 L08.9 
Cellulitis and abscess of unspecified site 682.9 L03.90, 
L02.91 
Impetigo 684 L01.00 
Staph skin infection 686.9, 
041.10 
L08.9, B95.8 
Other postoperative infection 998.59 T81.4XXA 
Thrush 112 B37.0 
Erythrasma 39 L08.1 
Scabies 133 B86 
Molluscum contagiosum 78 B08.1 
Herpes labialis 54.9 B00.1 
Herpes simplex 54.9 B00.9 
Herpes zoster 53.9 B02.9 
Shingles 53.9 B02.9 
Zoster 53.9 B02.9 
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Vascular, connective tissue, or granulomatous ICD 9 ICD 10 
Unspecified venous (peripheral) insufficiency 459.81 I87.2 
Vasculitis of skin 709.1 L95.9 
Vasculitis(Notable Code) 447.6 I77.6 
Connective tissue disease(Notable Code) 710.9 M35.9 
Connective tissue disease, undifferentiated(Notable 
Code) 
710.9 M35.9 
Cutaneous lupus erythematosus 695.4 L93.2 
Allergic purpura(Notable Code) 287 D69.0 
Atrophie blanche 701.3 L90.8 
Henoch-Schonlein purpura(Notable Code) 287 D69.0 
HSP (Henoch Schonlein purpura)(Notable Code) 287 D69.0 
Purpura(Notable Code) 287.2 D69.2 
Capillaritis 448.9 I78.8 
Morphea en coup de sabre 701 L94.0 
Localized morphea 701 L94.0 
Raynaud's syndrome 443 I73.00 
Hemangioma of skin and subcutaneous tissue 228.01 D18.01 
Leukocytoclastic vasculitis(Notable Code) 446.29 M31.0 
Facial telangiectasia 448.9 I78.1 
Pyogenic granuloma 686.1 L98.0 
Majocchi's granuloma 110.6 B35.8 
Granulation tissue of skin 701.5 L92.9 
Granuloma annulare 695.89 L92.0 
   
Folliculitis ICD 9 ICD 10 
Folliculitis 704.8 L73.9 
Pseudofolliculitis 704.8 L73.8 
Pseudofolliculitis barbae 704.8 L73.1 
Pseudofolliculitis of the beard 704.8 L73.1 
Pityrosporum folliculitis 704.8 L73.8 
   
Screening ICD 9 ICD 10 
Screening for malignant neoplasm of skin V76.43 Z12.83 
Screening for malignant neoplasm of the skin V76.43 Z12.83 
Screening for skin cancer V76.43 Z12.83 
Screening, malignant neoplasm, skin V76.43 Z12.83 
Screening exam for skin cancer V76.43 Z12.83 
Personal history of malignant melanoma of skin V10.82 Z85.820 
Personal history of other malignant neoplasm of skin V10.83 Z85.828 
Personal history of skin cancer V10.83 Z85.828 
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History of squamous cell carcinoma in situ V10.89 Z86.008 
Hx of squamous cell carcinoma of skin V10.83 Z85.828 
History  of basal cell carcinoma V10.83  
History of basal cell cancer V10.83 Z85.828 
Hx of atypical nevus V13.3 Z87.2 
History of squamous cell carcinoma of skin V10.83 Z85.828 
Family history of melanoma V16.8 Z80.8 
Skin exam, screening for cancer V76.43 Z12.83 
Skin cancer screening V76.43 Z12.83 
Encounter for screening for malignant neoplasm of skin V76.43 Z12.83 
   
Basal cell carcinoma ICD 9 ICD 10 
Basal cell carcinoma 173.91 C44.91 
Basal cell carcinoma of back 173.51 C44.519 
Basal cell carcinoma of brow 173.31 C44.319 
Basal cell carcinoma of chest wall 173.51 C44.519 
Basal cell carcinoma of eyebrow 173.31 C44.319 
Basal cell carcinoma of face 173.31 C44.310 
Basal cell carcinoma of left cheek 173.31 C44.319 
Basal cell carcinoma of nose 173.31 C44.311 
Basal cell carcinoma of right forehead 173.31 C44.319 
Basal cell carcinoma of right temple region 173.31 C44.319 
Basal cell carcinoma of skin of other and unspecified 
parts of face 
173.31 C44.319 
Basal cell carcinoma of skin of trunk 173.51 C44.519 
Basal cell carcinoma of skin, site unspecified 173.91 C44.91 
BCC (basal cell carcinoma of skin) 173.91 C44.91 
BCC (basal cell carcinoma), face 173.31 C44.310 
BCC (basal cell carcinoma), trunk 173.51 C44.519 
Recurrent basal cell carcinoma of ear 173.21 C44.211 
   
Squamous cell carcinoma ICD 9 ICD 10 
Squamous cell carcinoma in situ 234.9 D09.9 
Squamous cell carcinoma in situ of skin 232.9 D04.9 
Squamous cell carcinoma in situ of skin of deltoid 
region 
232.6 D04.60 
Squamous cell carcinoma in situ of skin of right cheek 232.3 D04.39 
Squamous cell carcinoma of back 173.52 C44.529 
Squamous cell carcinoma of skin of arm 173.62 C44.621 
Squamous cell carcinoma of skin of left upper limb, 
including shoulder 
173.62 C44.629 
Squamous cell carcinoma skin right ear and external 173.22 C44.222 
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auricular canal 
Squamous cell carcinoma, leg, right 173.72 C44.722 
Squamous cell carcinoma, scalp/neck 173.42 C44.42 
Squamous cell skin cancer 173.92 C44.92 
Squamous cell carcinoma in situ of skin of chest 232.5 D04.5 
Squamous cell carcinoma in situ of skin of face 232.3 D04.30 
Squamous cell carcinoma in situ of skin of forehead 232.3 D04.39 
Squamous cell carcinoma in situ of skin of left cheek 232.3 D04.39 
Squamous cell carcinoma in situ of skin of left forearm 232.6 D04.62 
Squamous cell carcinoma in situ of skin of neck 232.4 D04.4 
Squamous cell carcinoma of dorsum of right hand 173.62 C44.622 
Squamous cell carcinoma of left lower leg 173.72 C44.729 
SCC (squamous cell carcinoma), eyelid, right 173.12 C44.122 
SCC (squamous cell carcinoma) 173.92 C44.92 
SCC (squamous cell carcinoma), arm 173.62 C44.621 
SCC (squamous cell carcinoma), leg 173.72 C44.721 
   
Melanoma ICD 9 ICD 10 
Melanoma in situ of back(Notable Code) 172.5 D03.59 
Melanoma of groin(Notable Code) 172.5 C43.59 
Melanoma of skin(Notable Code) 172.9 C43.9 
   
Neoplasm of uncertain behavior or unspecified ICD 9 ICD 10 
Neoplasm of skin 239.2 D49.2 
Neoplasm of uncertain behavior 238.9 D48.9 
Neoplasm of uncertain behavior of back 238.8 D48.7 
Neoplasm of uncertain behavior of skin 238.2 D48.5 
Neoplasm of uncertain behavior of skin of chest 238.2 D48.5 
Neoplasm of uncertain behavior of skin of forehead 238.2 D48.5 
Neoplasm of unspecified nature of bone, soft tissue, and 
skin 
239.2 D49.2 
Carcinoma in situ of eyelid, including canthus 232.1 D04.10 
Other and unspecified malignant neoplasm of scalp and 
skin of neck 
173.4  
Other and unspecified malignant neoplasm of skin of 
other and unspecified parts of face 
173.3  
Carcinoma in situ of skin of other and unspecified parts 
of face 
232.3 D04.39 
Unspecified malignant neoplasm of skin of lip 173 C44.00 
Unspecified malignant neoplasm of skin of other and 
unspecified parts of face 
173.3 C44.300 
Other malignant neoplasm of skin of lower limb, 173.7  
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including hip 
Other malignant neoplasm of skin of trunk, except 
scrotum 
173.5  
   
Psoriasis ICD 9 ICD 10 
Arthritis with psoriasis(Notable Code) 696 L40.50 
Guttate psoriasis 696.1 L40.4 
Psoriasiform dermatitis 696.8 L30.8 
Psoriasis 696.1 L40.9 
Psoriasis and similar disorder 696.1 L40.8 
Sebopsoriasis 692.9 L30.9 
Other psoriasis 696.1 L40.8 
Plantar pustulosis 696.1 L40.8 
   
Ulcer, erosion, fissure, or wound ICD 9 ICD 10 
Decubitus ulcer, buttock, left, stage I 707.05, 
707.21 
L89.321 
Decubitus ulcer, stage 1 707.00, 
707.21 
L89.91 
Stage 1 decubitus ulcer 707.00, 
707.21 
L89.91 
Ulcer of perianal area(Notable Code) 707.8 L98.499 
Ulcer(Notable Code) 707.9 L98.499 
Ulcer, skin, non-healing(Notable Code) 707.9 L98.499 
Ulceration(Notable Code) 707.9 L98.499 
Ulcer of left lower leg, with fat layer exposed(Notable 
Code) 
707.1 L97.922 
Ulcer, skin, chronic, limited to breakdown of 
skin(Notable Code) 
707.9 L98.491 
Ulcer, skin, non-healing, limited to breakdown of 
skin(Notable Code) 
707.9 L98.491 
Skin ulceration, with fat layer exposed(Notable Code) 707.9 L98.492 
Chronic ulcer of left lower extremity with fat layer 
exposed(Notable Code) 
707.1 L97.922 
Chronic ulcer of leg, left, limited to breakdown of 
skin(Notable Code) 
707.1 L97.921 
Stomal ulcer 534.9 K28.9 
Skin fissures 709.8 R23.4 
Skin erosion(Notable Code) 709.9 L98.9 
Parastomal ulcer of enterostomy 534.9  
Peristomal skin breakdown(Notable Code) 707.9 L98.499 
Oral aphthae 528.2 K12.0 
Perleche 686.8 K13.0 
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Angular cheilitis 528.5 K13.0 
   
Warts ICD 9 ICD 10 
Condyloma 78.11 A63.0 
Condyloma acuminata 78.11 A63.0 
Condyloma acuminatum 78.11 A63.0 
Common wart 78.19 B07.8 
Plantar wart 78.12 B07.0 
Plantar wart, right foot 78.12 B07.0 
Plantar warts 78.12 B07.0 
Flat wart 78.19 B07.8 
Mosaic wart 78.19 B07.8 
Subungual warts 78.1 B07.9 
Verruca 78.1 B07.9 
Verruca plana 78.19 B07.8 
Verruca plantaris 78.12 B07.0 
Verruca vulgaris 78.1 B07.9 
Viral wart 78.1 B07.9 
Viral warts 78.1 B07.9 
Viral warts due to HPV 078.19, 
079.4 
B07.9 
Viral warts, unspecified 78.1 B07.9 
Viral warts, unspecified type 78.1 B07.9 
Wart 78.1 B07.9 
Wart viral 78.1 B07.9 
Warts 78.1 B07.9 
Other viral warts 78.19 B07.8 
Other specified viral warts 78.19 B07.8 
   
Follow up visit ICD 9 ICD 10 
Follow-up examination, following unspecified surgery V67.00 Z09 
Visit for suture removal V58.32 Z48.02 
Visit for wound check V58.89 Z51.89 
Suture check V58.49 Z48.89 
Postop check V67.00 Z09 
Postoperative examination V67.00 Z09 
Postoperative follow-up V67.00 Z09 
Encounter for long-term (current) use of other 
medications 
V58.69 Z79.899 
Pregnancy examination or test, negative result V72.41 Z32.02 
Research study patient V70.7 Z00.6 
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Vitiligo & skin pigmentation ICD 9 ICD 10 
Vitiligo 709.01 L80 
Dyspigmentation 709 L81.9 
Post-inflammatory hyperpigmentation 709 L81.0 
Hyperpigmentation of skin 709 L81.9 
Dyschromia 709 L81.9 
Dyschromia, unspecified 709 L81.9 
Other dyschromia 709.09 L81.9 
Melasma 709.09 L81.1 
   
Rash, puritis or scratching ICD 9 ICD 10 
Unspecified pruritic disorder 698.9 L29.9 
Excoriation 919.8 T14.8 
Rash 782.1 R21 
Rash and other nonspecific skin eruption 782.1 R21 
Generalized pruritus 698.9 L29.9 
Grover's disease 702.8 L11.1 
Pruritus ani 698 L29.0 
Prurigo nodularis 698.3 L28.1 
Prurigo 698.2 L28.2 
Urticaria 708.9 L50.9 
Urticaria, unspecified 708.9 L50.9 
Multiple excoriations 919.8 T14.8 
Neurotic excoriations 698.4 L98.1 
Dermal hypersensitivity reaction 692.9 L23.9 
Dermatographism 708.3 L50.3 
Other specified urticaria 708.8 L50.8 
Insect bite 919.4, 
E906.4 
W57.XXXA 
Other, multiple, and unspecified sites, insect bite, 
nonvenomous, without mention of infection  
919.4  
Papular urticaria 698.2 L28.2 
Morbilliform rash 782.1 R21 
Perianal irritation 698 L29.0 
   
Drug related ICD 9 ICD 10 
Long term use of drug V58.69 Z79.899 
Drug rash 693 L27.0 
Drug eruption 693 L27.0 
Phototoxic drug eruption 692.72, 
E947.9 
L56.0 
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Other ICD 9 ICD 10 
Dysesthesia 782 R20.8 
Erythromelalgia(Notable Code) 443.82 I73.81 
Neutrophilic dermatosis 695.89 L98.2 
Erythema ab igne 949.1 L59.0 
Hyperhidrosis 705.21 L74.519 
Primary focal hyperhidrosis 705.21 L74.519 
Generalized hyperhidrosis 780.8 R61 
Unspecified disorder of skin and subcutaneous tissue 709.9 L98.9 
Unspecified hypertrophic and atrophic condition of skin 701.9 L91.9, L90.9 
Other specified congenital anomaly of skin 757.39 Q82.8 
Other specified disease of hair and hair follicles 704.8 L73.8 
Other specified disorder of skin 709.8 L98.8 
Other specified erythematous condition(695.89) 695.89  
Other specified hypertrophic and atrophic condition of 
skin 
701.8 L91.8, L90.8 
Dupuytren's contracture of both hands 728.6 M72.0 
Facial swelling 784.2 R22.0 
Scrotal edema 608.86 N50.89 
   
Dry skin, skin peeling, scar or callous ICD 9 ICD 10 
Wrinkles 701.8 L90.8 
Facial rhytids 701.8 L90.8 
Xerosis cutis 706.8 L85.3 
Xerosis of skin 706.8 L85.3 
Dry skin 701.1 L85.3 
Hypertrophic scar of skin 701.4 L91.0 
Keloid 701.4 L91.0 
Scar 709.2 L90.5 
Scar condition and fibrosis of skin 709.2 L90.5 
Scars 709.2 L90.5 
Keratolysis exfoliativa 757.39 Q82.9 
Callus of foot 700 L84 
Corns and callosities 700 L84 
Lichen planus 697 L43.9 
Lichenification and lichen simplex chronicus 698.3 L28.0 
 
Abbreviations: ICD9 - International Classification of Diseases, Ninth Revision; ICD10 – 
International Classification of Disease, Tenth Revision 
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Table 20. Top five reasons for dermatologic care from IBD patients over the study period according 
to primary diagnosis code 
2010 (n=89 visits) n (%)* 
1. Contact Dermatitis or Dermatitis  24 (27.0) 
2. Neoplasm of uncertain behavior or unspecified 20 (22.5) 
3. Acneiform eruptions 8 (9.0) 
4. Benign neoplasm 6 (6.7) 
4. Hair loss or growth 6 (6.7) 
4. Warts 6 (6.7) 
2011 (n=261 visits)  
1. Contact dermatitis or dermatitis  76 (29.1) 
2. Acneiform eruptions 43 (16.5) 
3. Neoplasm of uncertain behavior or unspecified 24 (9.2) 
4. Benign neoplasm 15 (5.8) 
5. Actinic keratoses and solar skin aging 14 (5.4) 
5. Other 14 (5.4) 
2012 (n=256 visits)  
1. Contact dermatitis or dermatitis  42 (16.4) 
2. Acneiform eruptions 25 (9.8) 
3. Psoriasis 20 (7.8) 
4. Neoplasm of uncertain behavior or unspecified 19 (7.4) 
5. Benign neoplasm 17 (6.6) 
2013 (n=368 visits)  
1. Contact dermatitis or dermatitis  62 (16.9) 
2. Vitiligo 41 (11.1) 
3. Acneiform eruptions 34 (9.2) 
4. Psoriasis 34 (9.2) 
5. Benign neoplasm 25 (6.8) 
2014 (n=298 visits)  
1. Contact dermatitis or dermatitis  40 (12.5) 
2. IBD, pyoderma gangrenosum, hidradenitis 
suppurativa 
33 (10.3) 
3. Acneiform eruptions 32 (10.0) 
4. Warts 28 (8.7) 
5. Benign neoplasm 18 (5.6) 
2015 (n=298)  
1. Contact dermatitis or dermatitis  41 (13.8) 
2. Acneiform eruptions 32 (10.7) 
3. Actinic keratoses and solar skin aging 22 (7.4) 
4. Neoplasm of uncertain behavior or unspecified 21 (7.1) 
5. Warts 19 (6.4) 
2016 (n=313 visits)  
 108 
1. Contact dermatitis or dermatitis  46 (14.7) 
2. Screening 24 (7.7) 
2. Neoplasm of uncertain behavior or unspecified 24 (7.4) 
4. Nevus 23 (7.4) 
5. Acneiform eruptions 22 (7.0) 
5. Actinic keratoses and solar skin aging 22 (7.0) 
Total 2010 – 2016 (n=1906 visits)  
1. Contact dermatitis or dermatitis  331 (17.4) 
2. Acneiform eruptions 196 (10.3) 
3. Neoplasm of uncertain behavior or unspecified 144 (7.6) 
4. Benign neoplasm 107 (5.6) 
5. Actinic keratoses and solar skin aging 103 (5.4) 
5. Psoriasis 103 (5.4) 
Abbreviations: IBD – inflammatory bowel disease 
*Percentage of total dermatologic visits made by inflammatory bowel disease patients over each 
calendar year. 
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